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ABSTRACT
Glucuronides are hydrophilic and polar metabolites formed from nucleophilic substrates in 
phase II metabolic reactions. Glucuronidation is catalysed by UDP-glucuronosyltransferase 
enzymes (UGTs). The particular regio- and stereoisomeric glucuronides formed are 
determined by the structure of the substrate. Glucuronidation of (±)-O-desmethyltramadol 
(M1), the active metabolite of analgesic tramadol, yields a pair of diastereomeric 3-O-
glucuronides (M1Gs), and the antiparkinson drug entacapone yields diastereomeric 3-O-
glucuronides of entacapone and its (Z)-isomer (EG and EZG). These glucuronides were 
selected as test compounds in the experimental work.
The investigations summarised in this thesis deal with enzymatic glucuronidation and the 
development of analytical methods for drug metabolites, particularly diastereomeric 
glucuronides. Liquid chromatography (LC) with ultraviolet (UV) or mass spectrometric (MS)
detection, a well-established technique in metabolite analysis, was employed, and capillary 
electromigration techniques, which have good resolving power, were tested for their 
suitability in the separation of diastereomeric glucuronides. Fast and selective ultra 
performance liquid chromatography (UPLC) coupled with electrospray ionisation (ESI)-MS 
was applied as well.
Lack of commercial glucuronide standards has led to a search for enzymatic methods for their 
production. In this study, enzyme-assisted synthesis with rat liver microsomes (RLMs) was 
optimised to produce M1G diastereomers from small amounts of starting material, (±)-M1.
Glucuronide formation catalysed by RLMs was stereoselective and favoured the formation of 
1S,2S-diastereomer. The glucuronides were isolated by LC/UV, and UPLC/ESI-MS, while 
tandem mass spectrometry (MS/MS) and proton nuclear magnetic resonance (1H NMR) 
spectroscopy were employed in structural characterisation. Application of nuclear Overhauser 
effect spectroscopy (NOESY) established that the glucuronides were phenolic O-glucuronides 
of M1. When the diastereomers were isolated as a combined fraction the yield was 51% (6.5 
mg).
Screening assays were carried out to identify the human UGT enzymes that catalyse (±)-M1 
glucuronidation. The activity of human liver and intestinal microsomes was examined as well. 
The assays revealed that several UGT enzymes are able to catalyse (±)-M1 glucuronidation.
UGTs 1A7–1A10 are strictly enantiospecific for the 1R,2R-enantiomer, while UGT2B7 
glucuronidates both M1 enantiomers. Glucuronidation of (±)-M1 was also stereoselective in 
human liver microsomes (HLMs), and the activity largely resembled that of UGT2B7. It 
seems probable, therefore, that UGT2B7 is the main isoform involved in (±)-M1 
glucuronidation in human liver. 
Positive ion mode UPLC/ESI-MS was used to monitor (±)-M1 glucuronidation in incubation 
samples. Formation of M1Gs was quantified with the aid of synthesised reference 
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glucuronides. With its high resolution power, the UPLC technique provided a useful tool for 
the analysis of diastereomeric M1Gs, which cannot be differentiated by MS alone.
Further in the present work, several methods relying on capillary electromigration techniques
with UV detection were developed and optimised for qualitative and quantitative analysis of 
drug metabolites, particularly glucuronides. A capillary electrophoretic (CE) method was 
optimised for the separation of free and glucuronidated metabolites of tramadol, and its 
suitability was tested with an authentic urine sample after tramadol administration. In 
comparison with standards, tramadol and its metabolites M1, M1G, (±)-N,O-
didesmethyltramadol (M5) and its glucuronide (M5G) were easily detected in the 
electropherogram. Furthermore, diastereomeric separation of tramadol glucuronides—M1Gs,
(±)-N,N,O-tridesmethyltramadol glucuronide (M4Gs) and M5Gs—was achieved in acidic (pH 
2.75) background electrolyte (BGE) by CE, and in basic (pH 10.45) BGE by micellar 
electrokinetic chromatography (MEKC).
A MEKC/UV method was developed and optimised for direct quantitative determination of 
EG and EZG in urine. Urine samples were purified before analysis by solid phase extraction 
(SPE). The validity of the method was assessed by investigating several important analytical 
parameters. The limit of quantification (LOQ) for EG and EZG was 2 μg/ml (ca. 4 μM), and
the method was confirmed to be reproducible and accurate. Determination of EG and EZG 
concentrations in urine samples of 34 patients treated with entacapone showed the method to 
be suitable for monitoring  concentrations of EG after both oral and intravenous
administration and concentrations of EZG after oral administration. The long-term stability of 
the system is limited, however, and frequent recalibration is required in applications involving 
long sample series. 
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1 INTRODUCTION
Absorption, distribution, metabolism and elimination (pharmacokinetics) are key determining 
steps in drug action [1, 2]. Since all these steps are affected by the three-dimensional structure
of carrier proteins, enzymes and their targets, stereochemistry plays an important role in drug
action.
Drugs and foreign compounds are metabolised in the body in enzyme catalysed reactions,
which are typically divided into phase I and phase II reactions. Glucuronidation is an 
important phase II metabolic reaction in which the substrate (for example, a drug molecule) is 
conjugated with glucuronic acid [3]. The glucuronides formed in the reaction are water-
soluble and usually inactive metabolites that are readily excreted into urine or bile. 
Glucuronidation is catalysed by a family of metabolising enzymes called uridine 
diphosphoglucuronosyltransferases (UDP-glucuronosyltransferases, UGTs, EC 2.4.1.17),
which are expressed mainly in the liver but also in many other tissues. Most UGTs have broad 
and partly overlapping substrate specificities. Some UGTs display considerable 
stereoselectivity [4, 5]. The present availability of human tissue microsomes and recombinant 
UGTs has improved the means to study UGT-mediated drug metabolism in vitro and reveal 
individual UGTs (and potential polymorphic UGTs) in drug disposition.
Glucuronidation may produce different regio- and stereoisomers depending on the structure of 
the substrate. Glucuronidation of chiral compounds and geometric isomers yields a pair of 
diastereomers, which differ in their spatial geometry and are, in fact, different compounds. 
The differences in their physical and chemical properties may be slight, however, making
separation difficult. Another problem in diastereomer analysis is that the diastereomers can
seldom be differentiated by mass spectrometric (MS) detection methods [6]. Glucuronides 
with amine-containing side chains form a special group of analytically challenging 
compounds owing to their zwitterionic character. For these reasons, efficient separation is
usually required before the analysis of diastereomeric glucuronides.
Glucuronide conjugates are hydrophilic and polar compounds. Typically they are identified 
and quantified from complex biological matrices, such as urine, or from in vitro incubation
matrices that contain high concentrations of inorganic salts and microsomal proteins. 
Glucuronide concentrations in these matrices may be low. Thus, various pretreatment 
techniques are needed to purify, concentrate and isolate the analytes of interest and remove 
the disturbing compounds. Cleaner samples should also allow improved sensitivity and 
selectivity of the analysis and increase the life-time of the instruments. In addition to
pretreatment and good separation, sensitivity and selectivity of the detection are essential in 
the analysis of glucuronides.
Most of the bioanalytical methods used in glucuronide analysis rely on high performance 
liquid chromatography (HPLC) with ultraviolet (UV), fluorescence or more selective MS 
detection. Capillary electromigration techniques, known for their good resolving power, 
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rapidity and minimal sample and solvent consumption, gained popularity in the 1990s and 
have since then been used in glucuronide and enantiomer analysis. Micellar electrokinetic 
chromatography (MEKC) is a widely used separation technique for both charged and neutral 
analytes and is suitable for biological samples as well. The sensitivity of capillary 
electromigration techniques with UV detection is limited, however. A relatively new
approach in metabolic studies is ultra performance liquid chromatography (Acquity UPLC,
Waters Co; hereafter UPLC) coupled with electrospray ionisation (ESI)–MS. The benefits of 
UPLC compared with conventional HPLC are increased resolution and speed.
Lack of commercial glucuronide standards often hinders direct quantitative analysis of 
glucuronides. Production of glucuronides in enzyme-assisted synthesis with liver microsomes 
of laboratory animals is possible once ethical aspects have been addressed. Tandem mass 
spectrometry (MS/MS) and proton nuclear magnetic resonance (1H NMR) spectroscopy are 
invaluable in the structural characterisation of glucuronides.
In this work, study was made of alternative techniques for the analysis of diastereomeric drug 
glucuronides: liquid chromatography (LC) with UV and MS detection and capillary 
electrophoresis (CE) and MEKC with UV detection. In addition, nuclear magnetic resonance 
(NMR) spectroscopy was used in structural elucidation of the synthesised glucuronides. 
Diastereomeric glucuronides of tramadol and entacapone were employed as test compounds.
This thesis summarises the results of four experimental studies, reported in papers I-IV. The 
first paper deals with enzyme-assisted synthesis of O-desmethyltramadol glucuronides 
(M1Gs) and their isolation and structural characterisation. It also describes in vitro screening 
assays, which were carried out to examine (±)-O-desmethyltramadol (±)-M1) glucuronidation 
both in tissue microsomes and at the level of individual UGT enzymes. Special emphasis was 
on the stereoselectivity of glucuronidation. Several analytical techniques were needed to 
separate, isolate, characterise and quantify the diastereomeric M1Gs formed. The second 
paper reports a CE/UV method developed for the separation of tramadol and its free and 
glucuronidated metabolites in human urine. The suitability of the method was tested with an 
authentic urine sample after tramadol dosing. The third paper reports the development of a 
MEKC/UV method for the separation of the diastereomeric 3-O-glucuronides of entacapone 
and its (Z)-isomer (EG and EZG) in urine, while the fourth describes the validation of the 
MEKC method and evaluation of its suitability for quantitative bioanalysis in tests with urine
samples from patients after oral and intravenous administration of entacapone.
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2 REVIEW OF THE LITERATURE
The first three sections of the literature review focus on drug metabolism and glucuronidation.
The review covers the UGT enzymes that catalyse glucuronidation, the classification of the 
enzymes, substrate specificity and polymorphism. Special focus is on the stereoselectivity of 
UGT-catalysed reactions, which was a key topic in this work. Section four provides a 
description of stereoisomers, of which tramadol and entacapone are interesting examples.
Glucuronidation of these drugs and their metabolites yields diastereomers, which were the 
analytical targets of the study. The final section of the review deals with analytical
techniques—capillary electromigration techniques and LC/MS—used in the work to analyse 
diastereomeric glucuronide conjugates of tramadol and entacapone.
2.1 Drug metabolism
Drugs and other xenobiotics undergo numerous biotransformation reactions. An array of 
specialised enzymes catalyses metabolic reactions and protects the body against foreign 
substances [3, 7, 8]. Through these reactions, lipophilic exogenous compounds (drugs, 
environmental chemicals, dietary constituents) are converted almost always to more 
hydrophilic, more polar and more ionised forms to facilitate their excretion into urine or bile.
Many endogenous compounds, such as hormones, bilirubin and bile acids, undergo 
biotransformation as well. Metabolism is the major clearance mechanism for most drugs [9].
Although liver is the principal organ of drug metabolism, metabolic reactions take place in 
many other tissues as well including kidney, gastrointestinal tract, lung and even the skin.
Biotransformation reactions are generally divided into phase I and phase II reactions. 
2.2 Phase I metabolism
In phase I reactions, new polar functional groups are generated in a molecule through 
oxidative, reductive or hydrolytic reactions. Among the enzyme systems that catalyse these 
reactions the most important group is the cytochrome P450 (CYP) family of enzymes [9–11].
The metabolites formed in these reactions are excreted as such or may undergo phase II 
conjugations in which the newly formed functional groups (e.g., hydroxy -OH, carboxyl -
COOH, amino -NH2, sulfhydryl -SH) serve as attachment sites for conjugations.
In most cases, drug metabolism leads to the inactivation of the drug and excretion of 
metabolites [10]. Particularly in CYP-mediated reactions, drug metabolism can also lead to 
the formation of an active metabolite. According to a review, approximately 22% of the top 
50 prescribed drugs in the United States in 2003 were the kind that undergo biotransformation 
into pharmacologically active metabolites [8]. The biotransformation reactions that typically
lead to active metabolites are N- and O-dealkylations and aliphatic and aromatic 
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hydroxylations. For example, verapamil [12] and several antidepressants (amitriptyline, 
imipramine, fluoxetine) [8] undergo N-demethylation to active metabolites, O-demethylation 
of codeine yields morphine (Sanfilippo 1948, in ref. [13]), and aromatic hydroxylation of the 
cholesterol-lowering drug atorvastatin generates the active metabolites 2- and 4-
hydroxyatorvastatin [14]. Relative to the parent molecules, the structural changes in 
pharmacologically active metabolites tend to be small, and mostly occur at groups that are not 
crucial for proper binding to the target. It is not surprising therefore that metabolites have 
pharmacological actions similar to their parents [8]. Sometimes, however, a minor 
modification can result in loss of potency, as is the case with tramadol and venlafaxine: the O-
demethylated metabolite is active, whereas the N-demethylated metabolite is inactive [15, 16].
2.3 Conjugation reactions and glucuronidation
Several kinds of small, polar, endogenous molecules can be conjugated with xenobiotics or 
their metabolites. The enzymes that catalyse these phase II reactions are microsomal UGTs 
and nonmicrosomal cytosolic enzymes such as N-acetyltransferases, sulfotransferases,
glutathione S-transferases and methyltransferases. Glycine and other amino acids are also 
conjugated with drug molecules [7]. While glucuronidation is the principal conjugation 
reaction of most drugs, representing about 35% of all phase II reactions [17], nonmicrosomal 
conjugations also make an important contribution to the biotransformation of many
commonly used drugs. For example, paracetamol is metabolised to glucuronide and sulfate 
conjugates and its minor, oxidized reactive metabolite, N-acetyl-p-benzoquinone imine, to 
glutathione conjugates [10, 11] and acetylsalicylic acid to glucuronide and glycine conjugates
[18].
Glucuronidation reactions involve the UGT-catalysed transfer 
 -D-glucuronic acid (GA) 
from UDP--D-glucuronic acid (UDP-GA) to mostly lipophilic acceptors that have
nucleophilic O, N or S and rarely also C atoms in their functional groups [3, 7, 19]. Common
substrates are alcohols, phenols, carboxylic acids, amines and thiols. These reactions give rise 
to O-, N- and S-glucuronides. An uncommon C-glucuronidation occurs when a carbon atom is 
alpha to two electron-withdrawing carbonyl groups, as in pyrazolidinediones [20].
Glucuronidation of alcohols and phenols yields ether structured O-glucuronides (Fig. 1),
while ester O-glucuronides, better known as acyl glucuronides, are formed in reactions with 
carboxylic acids. The glucuronides always have a - configuration in the anomeric carbon of 
the pyranose ring. This stereochemical outcome of the reaction, inversion of configuration
(Fig. 1), indicates a bimolecular nucleophilic substitution (SN2) reaction [21, 22].
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Figure 1. Formation of an ether O-glucuronide of paracetamol in UGT-catalysed reaction. 
Glucuronidation is a nucleophilic SN2 substitution reaction.
The conjugation entails significant changes in the molecular size and shape and alters the 
physicochemical properties of the conjugate relative to the aglycone substrate [8, 23]. The pKa
value of glucuronic acid is 2.93 and the pKa values of the carboxylic acid in glucuronides are 
close to that value, in the range of 3–4 [24, 25]. Hence the glucuronides—as fairly strong 
acids—are completely ionised at physiological pH (7.4) and not likely to be reabsorbed by the 
renal tubules. The excretion of glucuronides into urine and bile usually takes place with the 
aid of specific efflux transporters such as multidrug resistance protein 2 (MRP2) [26].
Most glucuronide metabolites are not pharmacologically active. Some exceptions exist,
however, a classical example being morphine-6-glucuronide, which has analgesic activity and 
is even more potent than the parent drug [27, 28]. Also, the glucuronide of -
hydroxymidazolam is active and has caused prolonged sedation in patients with severe renal 
failure [29]. Furthermore, glucuronidation converts gemfibrozil to a potent inhibitor of 
CYP2C8 [30] and retinoic acid to a biologically active acyl glucuronide [31, 32].
Sometimes glucuronidation may generate short-lived metabolites [32, 33]. Acyl glucuronides
are glucuronide metabolites with high chemical reactivity. The reactivity originates from the 
ester group, which can be attacked by nucleophiles and engage in several reactions. These
labile glucuronides readily undergo both hydrolysis and intramolecular acyl group 
rearrangements (acyl migration). Furthermore, nucleophilic groups on proteins can react with 
the carbonyl carbon, yielding covalent protein adducts. Although many adverse and toxic 
effects of carboxylic acid-containing drugs have been attributed to acyl glucuronides, direct 
evidence for their toxicity is still limited and causality difficult to demonstrate. Examples of 
widely used carboxylic acid-containing drugs are nonsteroidal anti-inflammatory drugs 
(NSAIDs), diuretic furosemide and anticonvulsant valproic acid [33].
Although glucuronidation often is a “true” phase II reaction, many endogenous and 
exogenous compounds can be glucuronidated without prior phase I reactions. Endobiotics 
??
Paracetamol
UGTs
UDP 
UDP-?-D-glucuronic acid 
(UDP-GA)
Paracetamol??-D-glucuronide 
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such as bilirubin, steroids and bile acids and xenobiotics such as paracetamol (Fig. 1) [7],
morphine [34], oxazepam [4], entacapone (Fig. 4) [35], zidovudine (azidothymidine) [19] and 
NSAIDs [36] are primarily metabolised by direct glucuronidation.
2.3.1 Human UGT enzymes, classification and tissue localization
The human UGT enzymes responsible for glucuronidation belong to the UDP-
glycosyltransferase gene superfamily. The UGT enzymes that utilise predominantly UDP-
glucuronic acid as the glycosyl donor are classified into the three subfamilies UGT1A, 
UGT2A and UGT2B, on the basis of primary amino acid sequence and gene structure [37]
(Fig. 2). Within the subfamilies the amino acid sequences of UGT isoforms are at least 60% 
similar [3], whereas between families the similarity is less than 50% [7, 23, 38]. There are 19
functional human UGT proteins, nine of which belong to subfamily 1A, three to subfamily 2A 
and seven to subfamily 2B.
The human UGTs are membrane-bound enzymes of the endoplasmic reticulum (ER) with the 
active site situated in the ER lumen [39]. They contain, on average, 530 amino acids, which 
can be divided into two functionally important domains, the carboxy- and amino-terminal 
domains [3, 38]. The carboxy-terminal domain is highly similar in all UGTs and contains the 
UDP-GA binding site. A crystal structure of the carboxy-terminal domain and the co-
substrate binding site of human UGT2B7 has recently been presented by Miley et al. [40]. 
Additionally, Patana and co-workers have suggested two key residues involved in UDP-GA
binding of the human UGT1A6 [41]. The amino acids of the amino-terminal domain are more
Figure 2. The phylogenetic tree for UGT enzymes. The structural relationship and homology of 
human UGTs at the amino acid level is presented [23, 37].
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divergent, which is reflected in the ability of this domain to recognise and bind a variety of
molecules, which are glucuronidated. The amino-terminal domain is thought to be the binding 
site for the aglycone [42]. Although the detailed three-dimensional structure of the UGTs and
their active sites is not yet known, mechanistic studies conducted with recombinant human 
UGTs of the 1A subfamily support the theory that UDP-GA is the first-binding substrate [43].
Liver is the most important organ for UGT-catalysed biotransformations. Many UGTs are 
expressed in the liver [44, 45], while others, namely 1A5, 1A7, 1A8, 1A10, 2A1, 2A2 and 
2B11, are either expressed at very low levels in the liver or not at all [44–46]. The expression 
level of individual hepatic UGTs is also variable, and there are significant inter-individual 
differences in hepatic UGT expression [47]. UGTs are expressed in several other tissues 
besides the liver, and the UGT composition varies among tissues. 
2.3.2 Substrate specificity of UGTs
The UGTs generally display broad and overlapping substrate selectivity [19]. Phenols form 
one of the predominant chemical classes of UGT substrates. Several UGTs of subfamily 1A,
namely 1A1, 1A3, 1A7-1A10 [3] and 1A6 [43, 48], catalyse glucuronidation of different 
types of phenols with partly overlapping substrate specificities. Phenols and estrogen 
derivatives are also substrates for UGTs 2B4 [49], 2B7 [49, 50] and 2B15 [51]. The 
homologous UGTs 1A8 [52] and 1A9 [53] have somewhat similar substrate profiles, both 
catalysing glucuronidation of bulky phenols; interestingly, UGT2B15 shares several of these 
substrates [7, 51]. The homologous UGTs 2B4 and 2B7 also display distinct but overlapping 
substrate specificity [54]. An important substrate for UGT2B7 is morphine with both the
phenolic 3- and alcoholic 6-hydroxy groups as targets of glucuronidation [34, 55]. UGT2B7 is 
the only isoform that catalyses morphine-6-glucuronide formation, but several UGTs of the 
1A subfamily (e.g., 1A8) catalyse formation of morphine-3-glucuronide as well as other 
opioid glucuronides [55, 56].
A number of clinically important drugs are amines. While many UGT1 proteins catalyse 
primary and secondary amine glucuronidation, UGT1A4 is the main human UGT that 
converts tertiary aliphatic amines to quaternary ammonium glucuronides [57]. UGT1A4
conjugates other amines as well [58] and is therefore regarded as “an UGT specialised in N-
glucuronidation”. With respect to tertiary aliphatic amine glucuronidation, many animals
(e.g., rats) cannot produce functional UGT1A4 protein and are thus unable to glucuronidate 
these substrates [7, 57]. Recently, Kaivosaari and co-workers showed that human UGT2B10 
is the predominant UGT in nicotine glucuronidation [59], and it is also capable of 
glucuronidating other N-heterocycles [60].
Both endogenous and exogenous carboxylic acids are substrates of UGTs. Glucuronidation of 
bilirubin is probably the most important physiological conjugation reaction, in which the toxic 
breakdown product of haeme is converted to excretable glucuronide. The only human UGT 
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that specificially catalyses this reaction is UGT1A1 [61]. Hyodeoxycholic acid (HDCA) is a 
steroid structured bile acid that is mainly eliminated via glucuronidation. The key UGTs 
responsible for its detoxification are UGTs 2B4 [62] and 2B7 [49, 63]. Carboxylic acid-
containing NSAIDs are primarily cleared through glucuronidation, and multiple UGT 
enzymes, most notably, 1A1, 1A3, 1A9, 2B4, 2B7 and 2B17, catalyse these reactions [36].
UGT2B7 appears to glucuronidate structurally distinct NSAIDs such as ketoprofen and
ibuprofen as well as diclofenac and naproxen.
The chemical class or functionality of the substrate compound is not the only determinant of 
substrate specificity of UGTs. As with all enzyme-catalysed reactions, “right” stereochemistry 
of the compound is essential for recognition and binding to the active site. Hence the 
enantiomers of a racemic compound can behave very differently in homochiral biological 
environment, e.g., in enzyme reactions, because the active site of the enzyme can distinguish 
between the two mirror image molecules and will interact properly with only one of the 
enantiomers (Fig. 3) [64–66]. The interactions between the enantiomers and their biological 
targets are diastereomeric. A close fit between the substrate and the enzyme is a requirement 
in a specific reaction. Commonly, UGTs are regarded as flexible enzymes that can
accommodate structurally diverse substrates. Recent studies have, however, revealed a 
considerable degree of stereoselectivity associated with UGT-catalysed reactions [4, 5, 67–
69]. So far, the stereoselectivity of glucuronidation reactions and the UGTs mediating them 
has not been widely studied. Results of some studies are briefly presented below.
Figure 3. Hypothetical interactions between the two enantiomers of a racemic compound and the 
binding domain in the active site of the enzyme. The enantiomer depicted on the left can interact with 
all three “binding sites” b, c and d simultaneously and is a specific substrate for the enzyme. In
contrast, the enantiomer on the right cannot be aligned in the same way no matter how it is rotated in
space (Modified from ref. [65]).
Oxazepam is an antianxiety drug used as a racemate. Court and co-workers studied 
glucuronidation of racemic oxazepam and found that UGT2B15 selectively glucuronidates
(S)-oxazepam but shows no activity towards the (R)-enantiomer [4]. UGTs 1A9 and 2B7 are 
the main isoforms responsible for (R)-oxazepam glucuronidation.
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Flurbiprofen is one of the propionic acid-containing NSAIDs glucuronidated by several UGTs
[36]. Studies with racemic flurbiprofen showed UGT2B7 to exhibit highest activity towards 
this NSAID [70], and UGT2B7 is able to catalyse the formation of both (R)- and (S)-
glucuronides of flurbiprofen. However, the rate of glucuronidation of the (R)-enantiomer is
almost 3-fold that of its (S) counterpart. Earlier Tougou et al. observed that another NSAID, 
etodolac, is stereoselectively glucuronidated by human liver microsomes (HLMs) [71].
Glucuronidation studies with (S)- and (R)-etodolac and by recombinant human UGTs showed 
UGT1A9 to exhibit both the highest glucuronidation activity and marked stereoselectivity for 
(S)-etodolac.
Complex stereoselectivity is also observed in propranolol glucuronidation [5]. Two UGTs,
namely UGT1A9 and UGT1A10, conjugate propranolol enantiomers with opposite 
enantioselectivity, while UGTs 2B4 and 2B7 glucuronidate both enantiomers fairly similarly.
UGT1A9 primarily catalyses the formation of (S)-propranolol glucuronide, whereas
UGT1A10 prefers conjugation of the (R)-enantiomer. Further support for this finding was 
obtained in glucuronidation experiments with microsomes of human liver that lack UGT1A10 
and intestine that contains it. As expected, HLMs glucuronidate (S)-propranolol faster than 
(R)-propranolol, while the rates of glucuronidation with intestinal microsomes are the 
opposite. The results indicate that the above-mentioned UGTs contribute in an important way 
to the overall activity of these tissue microsomes.
Bichlmaier and co-workers investigated stereochemical events of UGT2B7- and UGT2B17-
catalysed reactions using secondary alcohols as substrates [67]. UGT2B7 and, particularly,
UGT2B17 display marked stereoselectivity, favouring glucuronidation of (R)-enantiomers 
over their respective (S)-enantiomers. The same UGTs 2B7 and 2B17 were further studied in
conjugation of endogenous steroids [68] and both were found to be stereoselective towards 
these substrates as well: 2B17 for the 17-OH of testosterone and 2B7 for the 17-OH of 
epitestosterone. Furthermore, UGTs 2B7, 2B15 and 2B17 glucuronidate four testosterone 
derivatives either at 3-OH or at 17-OH positions and exhibit large differences in regio- and 
stereoselectivities [69].
Taken together, UGTs can generally accept structurally diverse compounds as substrates, and 
one compound can be a substrate for several UGTs. Some UGTs have specific substrates 
(e.g., UGT1A1/bilirubin), and stereochemistry plays a critical role in substrate specificity of 
UGTs as well (e.g., UGT2B15/(S)-oxazepam). Such specific substrates can be utilised as 
selective probes in UGT activity testing. Clearly, the ubiquitously expressed UGT2B7 is an 
important isoform, since it accepts a wide range of clinically relevant substrates of both 
endogenous and exogenous origin.
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2.3.3 Polymorphism and clinical significance of UGTs
Many differences in pharmacological and toxicological effects of drugs have been traced to 
genetic polymorphism in drug-metabolising enzymes. Polymorphism has been observed in 
almost all UGTs—in 1A1, 1A3, 1A6–1A9, 2B4, 2B7, 2B15 and 2B28 [4, 23, 72–74].
Although toxic reactions related to polymorphism of UGTs are rare, allelic variants of
UGT1A1 gene are associated with serious diseases. Mutations in UGT1A1 gene complex 
either impair or completely prevent conjugation of bilirubin and cause severe metabolic 
disorders with highly elevated bilirubin levels [23, 61, 75, 76]. These inherited disorders 
comprise Crigler-Najjar syndromes type I (CN-I) and type II (CN-II) as well as Gilbert’s 
syndrome, which is the mildest form of these hyperbilirubinemias [77]. CN-I is a rare but 
severe disease, which without treatment leads to death. Because of the specific disposition of 
bilirubin the defect in UGT1A1 cannot be compensated by other UGTs. The allelic variant 
UGT1A1*28 that is associated with Gilbert’s disease may also reduce glucuronidation of 
drugs eliminated by UGT1A1 and increase their toxicity [75].
The most striking example of drug-induced toxicity is cancer therapy with irinotecan, which
in patients with UGT1A1*28 allele leads to accumulation of SN-38, the active and highly 
toxic metabolite of irinotecan [78, 79]. Geographical and inter-population variations are 
typical of genetic polymorphisms, and the frequency of UGT1A1*28 variant in Europeans is 
about 16% [80]. It may be important to note that the cholesterol-lowering drugs ezetimibe
[81], simvastatin and atorvastatin [82], widely used by Europeans, are metabolised by 
UGT1A1-mediated pathways in vitro.
According to current understanding, clinically significant drug–drug interactions are rarely 
due to UGT-mediated metabolism. Some reasons for this are the considerable redundancy of 
UGT enzymes as well as the clearly higher Km values of UGT substrates compared with those 
of CYPs [9, 83]. Various drugs, including many NSAIDs, have been identified as inhibitors of 
UGT-mediated reactions in vitro [83]. Furthermore, the enantiomers of a racemic compound 
that exhibit similar affinities towards the UGT enzyme may “compete” at the stage of the 
catalytic reaction and inhibit the other enantiomer.
2.4 Stereoisomers
Stereoisomers are compounds with the same structural formula and identical bonding 
sequence but different spatial arrangement of atoms. Stereoisomers are divided into geometric 
(cis–trans) isomers and isomers that contain stereogenic (chiral) centres.
Cis–trans isomerism exists when free rotation of carbon–carbon bonds is restricted either by a 
double bond or by a ring structure. The isomers have the same molecular formula, but
different spatial geometry and therefore different physical and chemical properties. Such
isomers, termed diastereomers, are different compounds and usually exert diverse
pharmacological effects as well. The alkene diastereomers can be interconverted only by 
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diastereomers are presented in Fig. 4.
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Figure 4. Two pairs of diastereomers. In 2-[(dimethylamino)methyl]-1-(3-
methoxyphenyl)cyclohexanol the cyclohexane ring prevents rotation and gives rise to two 
diastereomeric forms, of which the more active form on the left is known as tramadol [84].
Entacapone and its Z-isomer form a pair of diastereomers in which a double bond restricts rotation 
between the double-bonded carbons. Conversion of entacapone to its Z-isomer can take place if the 
molecule absorbs light or is heated. Isomerases present in various tissues also catalyse this 
conversion.
Chiral compounds, which form the other group of stereoisomers, are compounds with a
stereogenic centre, usually an asymmetric carbon atom. They exist as two enantiomers that 
are non-superimposable mirror images of each other. All their physical and chemical 
properties are identical, but the asymmetry of the molecule means that they rotate plane-
polarised light to opposite directions and are hence optically active. In an achiral environment 
the enantiomers undergo chemical reactions at the same rate, but, as noted above, they will be 
distinguished in enzyme reactions if the enantiomers react at different rates. This is because 
the enantiomers display diastereomeric interactions with the enzyme. These principles are 
exploited in chiral enantioseparation techniques, as discussed in Section 2.5. Resolution of 
enantiomers is based on formation of transient diastereomeric complexes between the 
enantiomers and a suitable chiral stationary phase (CSP). These complexes have different 
physicochemical properties. The enantiomers of tramadol are presented in Fig. 5.
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Figure 5. Tramadol is a racemic mixture of two enantiomers. The (+)-(1R,2R)-enantiomer is the 
more active enantiomer, or eutomer [84]. The less active -(1S,2S)-enantiomer is the distomer.
Naming of enantiomers is based on a system created by Cahn, Ingold and Prelog (CIP) [85].
Also known as the R,S convention, the CIP system specifies the two possible arrangements of 
atoms or groups attached to the asymmetric carbon according to their relative priorities. (The 
priority rules are not discussed here.) The configuration of the stereogenic centres is assigned 
with prefixes R and S, and for racemates the symbols RS and SR are used. Frequently, only the 
relative configuration is known, in which case the lowest numbered stereogenic centre serves 
as a reference and is always RS. Chemical Abstracts recommends an alternative system in 
which the lowest numbered stereogenic centre is arbitrarily assumed to be R* and the 
configurations of the other centres are denoted as R* or S* relative to it [86]. All symbols are 
starred, which means that the configurations are relative, not absolute.
The cis–trans system designates the structure of alkene isomers unambiguously only when 
one substituent is bonded to vinylic carbons. In the case of tri- and tetrasubstituted alkenes,
the system cannot clearly specify which substituent is cis or trans to which [87]. Therefore 
IUPAC prefers naming cis–trans alkene isomers according to the E/Z system, which is based 
on relative priorities of the substituents. The isomer with high-priority groups on opposite 
sides of the double bond has E configuration, and the isomer with groups on the same side has
Z configuration (Fig. 4). Similarly, use of the cis–trans system for 1,2 tri- or tetrasubstituted 
cyclohexanes is misleading and violates the priority rules. The configuration can be 
designated without confusion by using the R,S convention, as shown for tramadol in Fig. 5.
The complex stereochemistry of tramadol and entacapone makes these two compounds
interesting targets for study.
2.4.1 Metabolism of tramadol
Tramadol hydrochloride, (1R*,2R*)-2-[(dimethylamino)methyl]-1-(3-
methoxyphenyl)cyclohexanol hydrochloride, is a synthetic, centrally acting analgesic that has 
both structural and pharmacological features of opioids. Tramadol has two stereogenic centres
in its structure and it is marketed as a racemate [88] (Fig. 4 and 5). The enantiomers, the more 
*
* *
*
1
2
1
2
(+) -(1R,2R)                                   (-) -(1S,2S)  
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active (+)-(1R,2R) and the less active (-)-(1S,2S), act through different mechanisms but in a
complementary and synergistic manner [84, 89]. Compared with single-enantiomer treatment,
the racemate is regarded as the preferred formulation [90]. Tramadol is metabolised in 
mammals via N- and O-demethylation followed by phase II reactions in which the O-
demethylated phenolic compounds are conjugated with glucuronic acid or sulfate before 
excretion via the urine [91–93]. Only one of the metabolites, O-desmethyltramadol, 
(1R*,2R*)-2-[(dimethylamino)methyl]-1-(3-hydroxyphenyl)cyclohexanol, has analgesic 
activity [15]. The O-demethylation of tramadol, catalysed by polymorphic CYP2D6 [88, 94]
is highly stereoselective [95]. A substantial degree of stereoselectivity is associated with the 
pharmacokinetics of tramadol and O-desmethyltramadol as well [96–100]. Hence, tramadol 
and its metabolites, particularly the little studied glucuronide conjugates, represent a
challenging area for biosynthetic and bioanalytical research. The glucuronides formed from a 
pair of enantiomers are diastereomers and can therefore be separated. However, it is worth 
mentioning that the amine-structured glucuronides exist mainly as zwitterions in the pH range 
from ~3 to ~11. This provides an extra challenge for their analysis.
2.4.2 Metabolism of entacapone
L-Dopa in combination with carbidopa or benserazide is the mainstay of Parkinson therapy
[101]. Entacapone, which is (2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-
propenamide (Fig. 4), is a selective and efficient inhibitor of catechol-O-methyl transferase 
(COMT) and used as an adjunct in the treatment of the disease [101]. By inhibiting the O-
methylation of L-dopa, entacapone increases its bioavailability. More L-dopa enters the brain 
and is decarboxylated to dopamine, which alleviates the motor dysfunction of the disease
[102].
The metabolism of entacapone has been thoroughly investigated [35]. A small amount of 
entacapone, that is, the (E)-isomer of the molecule, is converted to an active metabolite, the 
(Z)-isomer, by isomerases present in the intestine, in the liver and in plasma (Fig. 4).  
Glucuronide conjugates represent about 95% of the urinary metabolites of entacapone and
make entacapone a highly suitable target for bioanalytical glucuronide research. Furthermore, 
considerable amounts of entacapone and its metabolites are probably eliminated through bile 
and faeces [35].
Two regioisomeric phenolic O-glucuronides are possible for entacapone and its (Z)-isomer. In 
humans only 3-O-glucuronides are formed [103], and the UGTs responsible for the selective 
glucuronidation of the phenolic 3-hydroxy group are the UGTs 1A9 [58, 104, 105] and 1A7, 
1A8 and 1A10 [43, 105]. The glucuronides of entacapone and its (Z)-isomer are 
diastereomers of each other.
26 
 
2.5 Analysis of stereoisomers
This section describes the analysis of glucuronide diastereomers. The analysis of enantiomers 
is briefly examined.
Direct analysis of glucuronide conjugates is not a straightforward task. The glucuronide 
standards needed for method development and quantification are seldom commercially 
available. In such cases, indirect methods based on enzymatic or chemical hydrolysis of 
glucuronides and subsequent determination of the released aglycone have been used instead, 
as described for the glucuronide of O-desmethyltramadol [106, 107] and for the glucuronides 
of entacapone and its (Z)-isomer [35]. Sometimes indirect methods are necessary because of 
the instability of the glucuronide conjugates, as is the case with many acyl glucuronides [33].
Indirect methods are always time-consuming, however, and to be reliable they require 
complete hydrolysis of the conjugates. Furthermore, site- or diastereomer-specific
information on the conjugates cannot be obtained with indirect methods of analysis.
Various approaches have been utilised to obtain glucuronides for purposes of direct analysis.
Enzymatic glucuronidation relying on liver microsomes of laboratory animals offers a 
practical pathway to produce -anomeric glucuronides in small scale [108–112] once ethical 
aspects have been addressed. Chemical methods of synthesis have been described for many 
glucuronides [113–116] including the glucuronides of O-demethylated tramadol metabolites
[117], but the methods often yield mixtures of - and -anomers and side-products.
Glucuronides can also be isolated and purified from urine of humans [118] or laboratory 
animals [119] after administration of the parent compound. Unambiguous characterisation of 
synthesised and isolated glucuronides requires MS analysis and NMR spectroscopy in cases 
where several regioisomeric and/or diastereomeric products are possible [112].
Capillary electromigration techniques and HPLC are the main techniques used in direct
analysis of polar glucuronide conjugates (described in Sections 2.5.1 and 2.5.2, respectively),
and the same achiral techniques are suitable for diastereomeric glucuronides. The 
glucuronides are usually identified in complex biological matrices where they exist in low 
concentrations. Sample clean-up and concentration procedures are often necessary to improve 
selectivity and sensitivity of bioanalysis [120] and also to increase the life-time of the 
capillaries and columns. Commonly employed sample preparation techniques are protein 
precipitation and centrifugation, solid-phase extraction (SPE), liquid–liquid extraction (LLE),
ultrafiltration or simple filtration. When glucuronides are analysed in in vitro incubation 
matrices, protein precipitation and centrifugation are often sufficient clean-up steps [4, 46, 68, 
69, 112, 121].
More than 50% of marketed drugs are chiral and the majority of them are used in therapy as
racemates [2, 66]. Frequently, however, the pharmacological activity resides in one 
enantiomer only and the other enantiomer is less active, inactive or even toxic. In the case of 
D,L-dopa, for example, the D-isomer is highly toxic and single-enantiomer therapy is the only 
choice [122, 123]. Such marked differences in pharmacological and toxicological profiles of 
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enantiomers have led to stricter requirements for chiral drugs and have rapidly increased the 
demand for enantioselective analysis methods that enable evaluation of the individual 
enantiomers. Chiral drugs, either as single enantiomers or as racemates, can be analysed by
capillary electromigration techniques or by chromatographic techniques such as HPLC, gas 
chromatography (GC), supercritical fluid chromatography (SFC) and thin layer 
chromatography (TLC) [2, 66, 124]. Chiral selectors or CSPs are, always, needed in these 
enantioseparations. Racemisation may sometimes complicate the analysis of enantiomers; for 
example, 3-hydroxylated benzodiazepines rapidly racemise in polar solvents [125, 126].
Capillary electromigration techniques and LC, the techniques utilised in the present work, are 
discussed in the following sections.
2.5.1 Capillary electromigration techniques
The feasibility to perform zone electrophoresis in glass or Teflon tubes was early 
investigated by Hjertén [127], Virtanen [128] and Mikkers with co-workers [129]. Interest in 
capillary electrophoresis (CE) was sparked when Jorgenson and Lukacs (1981) demonstrated 
that highly efficient electrophoretic separations can be obtained in narrow-bore, 75 μm 
capillaries [130]. Today, capillary electromigration techniques comprise a family of related 
separation techniques in which the separation takes place in narrow capillaries in electric 
field, but the principles of separation vary [131-135]. The applications cover a wide range of 
different classes of analytes, from small inorganic and organic ions to complex proteins and 
macromolecules such as DNA, for example. Miniaturisation of the techniques, first 
accomplished in 1992, marks the new era of chip-based separations [136]. Conventional CE 
and MEKC (or micellar electrokinetic capillary chromatography, MECC) and the basic 
theories behind them are briefly presented in the following. The main focus is on the analysis 
of drug metabolites, particularly drug glucuronides. The terminolology used follows IUPAC 
recommendations [131].
A central factor in any CE separation is electroosmotic flow (EOF). In aqueous solution 
(pH>2) [131, 137, 138] the surface of the fused silica capillary is negatively charged due to 
deprotonation of silanol groups (pKa ~ 5.3) [139]. Cations in electrolyte solution tend to form 
an electrical double layer at the silica–solution interface (Fig. 6), and the double layer,
composed of a diffuse and a stagnant layer [139, 140], creates a potential difference, the 
electrokinetic potential -potential), near the capillary wall. When an electric field is applied 
across the length of the capillary the solvated cations in the diffuse layer migrate towards the 
cathode and drag solvent with them [141]. This flow is electroosmosis. The nearly uniform 
flow in the capillary results in an almost ideal flat flow profile (Fig. 6) [130, 131, 141].
Compared to the parabolic flow profile of pressure-driven systems (LC) the plug-like flow 
causes very little zone dispersion. Hence narrower peaks and better resolution are obtained.
The plug flow also results in high separation efficiency [130, 131].
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2.5.1.1  Capillary electrophoresis
CE (formerly capillary zone electrophoresis, CZE), the simplest mode of capillary 
electromigration techniques, is used for the separation of charged analytes. In background 
electrolyte (BGE) charged analytes migrate under the influence of electric field towards the 
oppositely charged electrode. Migration velocity depends on the charge and size [130] and 
also the shape of the analytes [142]. Separation is hence based on differences in 
electrophoretic mobilities, μep, of analytes described by the equation 
μep = ze / 6   rad (1)
where z is the number of elementary charges on the ion and e is the elementary charge,  is 
the  viscosity of BGE and rad is the ion’s radius. From equation (1) it is clear that 
electrophoretic mobilities are higher for small, multiply charged analytes than for large, singly 
charged molecules, as depicted in the schematic illustration of a CE separation in Fig. 6. The 
degree of dissociation of acidic and basic groups affects the electrophoretic mobility of the 
solute, and the effective electrophoretic mobility, μeff, is the sum of all the electrophoretic 
mobilities of all dissociable groups [143].
Figure 6. Separation of cations (C), anions (A) and neutral (N) compounds in electric field. Positive 
ions form an electrical double layer. When an electric field is applied, the solvated cations of the
diffuse layer migrate toward the cathode resulting in an EOF with a flat profile. The small doubly 
charged cations are swept to the detector (at the cathodic end) first, while the small doubly charged 
anions reach the detector last.
The importance of EOF in CE separations is obvious. With the EOF, ions of a variety of sizes
and charges can be separated in a single run [130]. Thus the overall electrophoretic mobility
of a charged analyte; known as apparent mobility, μapp, is the sum of the ion’s effective
electrophoretic mobility, μeff, and EOF mobility, μeo [130, 144] (eq. 2).
μapp = μeff + μeo (2)
The neutral compounds are carried to the detector with EOF but are not separated (Fig. 6).
29 
 
The pH of the electrolyte solution has a crucial role in CE separations, since it influences both 
the EOF and the ionisation of the analytes. An increase in pH (particularly in pH range from 4 
to 8) increases the EOF [145], while a decrease in pH decreases the -potential and the 
magnitude of EOF owing to protonation of the silanol groups [137, 138]. Furthermore,
electrolyte type [142] and concentration have an effect on EOF, with high electrolyte 
concentrations decreasing its flow velocity [146]. Thus the EOF, although beneficial in most
separations, is governed by several interrelated variables that are often difficult to control in 
uncoated silica capillaries. It is important, therefore, to maintain constant pH and to use 
electrolyte solutions with good buffering capacity yet low conductivity to minimise current 
generation and Joule heating [147]. Heating can cause radial temperature gradients, change 
viscosity of the BGE and give rise to zone broadening [141].
One of the benefits of CE is its wide versatility. Thus selectivity of conventional CE can 
easily be modified through the introduction of suitable additives to the BGE. Separation of 
enantiomers can be accomplished with chiral additives. Cyclodextrins (CDs) are widely used 
chiral additives [133, 148–151] with which the enantiomers form transient diastereomeric 
inclusion complexes with different equilibrium constants [133, 148–151]. The formation of 
complexes results in different μeff of the enantiomers [150]. Structurally CDs consist of six, 
seven or eight D-glucose units connected by -(1,4) glycosidic linkages -- -CDs)
[133, 149, 150]. A large number of CDs, both native and derivatised, are used in chiral CE
thanks to their broad selectivity, reasonable solubility in aqueous solvents, and low UV 
absorbance [133, 150–151].
2.5.1.2  Micellar electrokinetic chromatography
Addition of ionic surfactants to the electrolyte solution at concentrations sufficient to form a 
micellar phase was pioneered by Terabe and co-workers [152]. This approach, commonly 
known as MEKC, widens the applicability of CE to neutral compounds. The most commonly 
used anionic surfactant is sodium dodecyl sulfate (SDS), which forms negatively charged 
micelles [153]. The micelles form a pseudo-stationary phase into which particularly the 
neutral analytes will partition (Fig. 7) resulting in retention and separation based on
chromatographic principles [138, 152]. For charged analytes the micelles provide additional 
interaction possibilities, and the separation thus relies on both chromatographic and 
electrophoretic mechanisms. The critical micelle concentration (CMC) of SDS in pure water 
is 8.1 mM (at 25 °C), but clearly lower CMC values are obtained in electrolyte solutions
[153]. The use of MEKC mode is particularly beneficial in bioanalytical applications since the 
micelles both diminish solute–wall interactions and break drug–protein complexes [154, 155].
A schematic illustration of an MEKC separation is presented in Fig. 7.
Several factors influence the success of analysis in quantitative capillary electromigration 
techniques. Samples can be introduced hydrodynamically with pressure or vacuum. The 
widely used pressurised injection mode forces sample components into the capillary 
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irrespective of their charge and electrophoretic mobility; thus the injected portion, typically a 
few nl, well represents the sample solution. Since several factors (e.g., temperature) will 
affect the actual volume injected, an internal standard (IS) is frequently added to compensate 
for the differences, particularly where analytes are present in complex matrices [156]. Use of 
IS, preferably with similar electrophoretic mobility to the analytes, often improves 
performance in capillary electromigration techniques, and precision values below 1% relative 
standard deviation (RSD) are obtainable [156, 157].
Figure 7. An MEKC separation with sodium dodecyl sulfate (SDS) as anionic surfactant. Partitioning 
of neutral compounds (N) with a micelle: cations (C) and anions (A). (The counterion Na+ is not 
shown.)
Detection of analytes in capillary electromigration techniques most often takes place on-
capillary through the capillary wall by spectrophotometric methods [129, 130, 133, 158].
Ultraviolet–visible (UV-Vis) absorbance detection is widely used, although the short optical 
path length together with small sample volumes limits the sensitivity of detection [133, 158].
Limits of detection (LODs) (without preconcentration of solutes) are in the 1–10 μM range
[158]. Sensitivity can be improved, however, by in-capillary sample concentration techniques 
[159, 160] and by using wavelengths down to 190–200 nm [161, 162]. In contrast to HPLC, 
analytes in electromigration techniques do not pass the detection window with a constant 
velocity [163, 164]. Low-mobility analytes will rest longer in the detection window and give a 
longer response and, as a result, peak areas will be larger. Corrected peak areas (normalised
by dividing the peak area by its migration time) are thus common in capillary 
electromigration techniques.
For applications in metabolite research, CE has often been hyphenated with powerful 
detection techniques such as extremely sensitive laser-induced fluorescence (LIF) [165, 166]
or sensitive and selective MS detection. Electrospray ionisation (ESI) (described in Section 
2.5.2) is by far the most popular CE/MS interface [167]. According to three review articles
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[167–169], CE/ESI-MS can provide sensitivities adequate for the monitoring of drugs and 
their metabolites in biological fluids. The reduced risk for ion suppression is a clear advantage 
of the CE/ESI-MS combination as compared with LC/ESI-MS [169]. However, the more 
mature LC/ESI-MS continues to play a leading role in the field of drug analysis. When 
MEKC/MS is employed, different strategies (e.g., partial filling technique) must be adopted to 
prevent contamination of the instrument by SDS micelles [160].
Capillary electromigration techniques provide a powerful alternative especially in the field of 
enantioselective analysis, owing to their high separation efficiency, simplicity, flexibility and 
low cost. A great number of papers dealing with CE enantioseparations of drugs or their 
metabolites have been published, but only a few recent studies, presented shortly below, have 
focused on the analysis of “covalent diastereomers” such as glucuronides. 
Baldacci and Thormann used CE/MS with negative ion ESI to confirm the presence of 
lorazepam 3-O-glucuronide in human urine after administration of (±)-lorazepam [170]. A
MEKC/UV analysis revealed unequal amounts of diastereomeric lorazepam glucuronides.
The same diastereomers were also formed in vitro when (±)-lorazepam and UDP-GA were
incubated with HLMs. Both results indicate stereoselective glucuronidation of lorazepam in 
humans. In another interesting study, Kim and Wainer monitored glucuronidation in neutrally 
coated capillaries using on-line CE/UV. RLMs, the substrate (4-methyl-7-hydroxycoumarin 
or 4-nitrophenol) and UDP-GA were injected into a capillary that contained polyacrylamide
gel [171]. The enzyme reaction took place within 15 min as the substrate and UDP-GA 
migrated through the almost immobile microsomal zone. The kinetic constants (Km and Vmax)
were determined for the glucuronidation of these compounds, and no significant differences 
were found between the on-line and off-line glucuronidation. Cho’s group, on the other hand, 
determined urinary androgen glucuronides by CE using negative ion ESI tandem mass 
spectrometry (MS/MS) [172]. LODs of the method were lower than 10 ng/ml. Although 
filtration was the only sample preparation step, both intra-day and inter-day coefficients of 
variation were less than 10%. The potential of microchip CE was studied by Starkey et al. 
[173]
	
	
	-glucuronidase and the Km value for the 
enzyme was determined both by microchip CE and by the conventional CE mode. Similar Km
values were obtained.
2.5.1.3 Capillary electromigration techniques in analysis of tramadol and entacapone 
metabolites
CD-mediated CE has been successfully applied in enantioseparations of tramadol and its 
phase I metabolites. Methyl--CD [165, 174], carboxymethyl--CD [97, 98, 165], sulfobutyl 
ether -CD [175, 176] and highly sulfated (HS)--CD [177] have been used as chiral 
selectors, commonly at pH 2.5 or at pH around 10 [97, 165]. Besides UV detection, LIF [165]
and ESI-MS [175] have been employed for the detection in chiral CE of tramadol metabolites.
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A particular benefit of CE is the possibility to analyse compounds with different polarities in 
a single run. This feature was exploited in a study in which tramadol, its four phase I 
metabolites and the glucuronide of O-desmethyltramadol were simultaneously separated in 
basic (pH 10.6) electrolyte solution with UV detection [97]. Using very similar conditions in 
CE/LIF analysis, Soetebeer et al. [165] detected O-desmethyltramadol glucuronide in urine as 
a single peak at pH 10.6, but were able to separate the diastereomeric glucuronides of O-
desmethyltramadol in acidic electrolyte solution (pH 3). 
The applicability of CE/ESI-MS in the analysis of entacapone glucuronides in urine has been 
examined by Keski-Hynnilä et al. [178]. Direct, CE/ESI-MS and CE/ESI-MS/MS methods 
were developed for quantitative analysis, with LODs in the CE/ESI-MS/MS mode 7 ng/ml for 
the glucuronides of both entacapone and its (Z)-isomer.
2.5.2 Liquid chromatography
LC with UV or MS detection is a well-established technique in bioanalytical chemistry.
Reversed phase (RP) LC using silica-based C18 or C8 stationary phases is well suited for the 
analysis of hydrophilic glucuronide conjugates. In acidic eluent systems (pH 2.0–4.0), polar 
glucuronides are converted to uncharged form, which favours their retention [179, 180].
Gradient elution is often beneficial when several analytes, such as metabolites with large 
differences in retention, need to be determined in a single chromatographic run [181].
A large number of LC methods with UV or fluorescence detection have been published for 
the analysis of glucuronide conjugates. LC/UV methods with semi-preparative [108, 116,
182] and analytical columns [112, 182] have been employed in the isolation of bio- or 
chemically synthesised glucuronides from reaction mixtures. For many bioanalytical 
applications the sensitivity and selectivity of LC/UV is insufficient, however.
LC coupled with MS is a universal and robust technique that meets the demands of sensitive 
and selective analyte detection even in complex biological matrices. Ever since the 
introduction of atmospheric pressure ionisation (API) techniques, LC/MS has been the main 
approach in clinical laboratories and in the pharmaceutical industry, where it is used in early 
discovery work to screen substances for metabolic properties [120, 181]. ESI is a “soft”
ionisation process that takes place at atmospheric pressure [183]. A liquid stream that contains 
the analytes in ion form is sprayed through a high voltage capillary. A fine spray of charged 
droplets is formed, whereafter the ions are emitted to gas phase by either “ion evaporation”
[184] or ”charge residue” [185] mechanism. Only polar, volatile solvents such as methanol, 
acetonitrile and water (with acetic acid or ammonium acetate) are compatible with the ESI 
interface [186]. Positive ion mode ESI has been shown to efficiently ionise glucuronides with 
basic or neutral groups [187] and positive ion LC/ESI-MS has been widely used in the 
analysis of glucuronide metabolites [6].
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An important factor to be noted in bioanalytical LC/MS applications is that the ESI interface 
is prone to ion suppression by polar matrix compounds [188–190]. In quantitative LC/MS 
analysis, a chromatographically co-eluting IS with high structural similarity to the analytes 
must be used to compensate for changes in the interface performance.
Chromatographic separation in metabolite analysis and pharmacokinetic studies can also be 
achieved with capillary LC systems. Capillary LC columns (typically 180–320 μm i.d.) are 
volumetrically smaller than conventional analytical columns (2–4.6 mm i.d.) of equivalent 
lengths [191], and because samples in capillary columns are diluted over a smaller column 
volume, better sensitivity is obtained. When ESI-MS detection is used, the improvement in 
sensitivity is dramatic. The benefits of capillary LC/ESI-MS technique become evident in 
pharmacokinetic studies in which low volume samples containing very low concentrations of 
drugs and their metabolites must be analysed. Typically, with sample volumes of 100-250 μl,
LOQ values in the region of 0.1–1 ng/ml can be achieved. In a recent study, Jäntti and co-
workers [192] identified and quantified ten brain steroids and their two sulfate and nine
glucuronide conjugates in mouse brain using capillary LC/ESI-MS/MS. LOD values for 
steroid glucuronides ranged from 6 to 80 pmol/l.
Another approach in the field of fast chromatographic separation techniques is UPLC. Use of
columns with small 1.7-μm particles delivers increased speed, sensitivity and resolution [193,
194]. The small particle size of columns demands an efficient pumping system, and the 
Waters Acquity UPLC is the first commercially available device designed to operate at high 
pressures up to 15 000 psi (about 1000 bar). The sharp peaks produced in UPLC are
particularly advantageous when UPLC is coupled to ESI-MS: ionisation efficiencies are 
improved and sensitivity and spectral quality in both MS and MS/MS modes are superior
[195, 196]. Clearly improved LC/MS sensitivity was obtained for UPLC/ESI-MS/MS as 
compared with HPLC/ESI-MS/MS [197] and also for UPLC/MS as compared with a
monolithic LC/MS system [196]. Additionally, in the latter study, more phase II metabolites 
of paracetamol were detected with the UPLC/MS approach [196], and UPLC was also able to 
resolve the two glucuronides of midazolam that were unresolved in the HPLC analysis [195].
UPLC-MS/MS was also successfully applied to the determination of UGT2B7 activity in 
HLMs with azidothymidine as selective substrate [198].
2.5.2.1 Glucuronides of tramadol and entacapone as targets of liquid chromatographic
analysis 
Only a few papers have been published concerning HPLC analysis of tramadol glucuronides.
Overbeck and Blaschke [199] employed ion pair RPLC with fluorescence detection in the 
determination of the diastereomeric glucuronides of O-desmethyltramadol, O,N-
didesmethyltramadol and O,N,N-tridesmethyltramadol in human urine and found that all three 
tested volunteers excreted glucuronides predominantly as (1S,2S)-diastereomers. Wu et al. 
34 
 
studied tramadol metabolism in rat and dog [92] and in humans [93] and identified seven 
glucuronide metabolites in human urine on the basis of ionspray-MS/MS data.
Negative ion mode LC/ESI-MS/MS has been used to analyse glucuronides of entacapone and 
its (Z)-isomer in urine [200] and in plasma [201]. The study in urine showed that 
fragmentation of the deprotonated glucuronide molecules took place with the glucuronide 
moiety cleaved off as a neutral species [200]. It also revealed that the diastereomeric 
glucuronides of entacapone and its (Z)-isomer cannot be distinguished on the basis of ESI-MS 
spectra. Keski-Hynnilä et al. [202] additionally demonstrated that entacapone glucuronide, 
without any basic structure, can be analysed by positive ion mode LC/ESI-MS.  
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3 AIMS OF THE STUDY
The primary aim of the research reported here was to biosynthesise O-desmethyltramadol
glucuronides as reference compounds and to examine the catalytic activity of UGT enzymes 
in (±)-O-desmethyltramadol glucuronidation. Further aims were to develop qualitative and 
quantitative methods based on capillary electromigration techniques and liquid
chromatography with UV and MS detection for the bioanalysis of tramadol metabolites and 
glucuronides of entacapone and its (Z)-isomer.
Specifically the aims of the research (I-IV) were:
 To biosynthesise diastereomeric glucuronides of (±)-O-desmethyltramadol, 
characterise their structure and use them as reference standards in activity and kinetic 
studies; to study the activity of recombinant human UGTs and of human liver and 
intestinal microsomes in (±)-O-desmethyltramadol glucuronidation with the main 
focus on the stereoselectivity of these reactions (I).  
 To develop a capillary electrophoretic method for separation of tramadol and its main 
phase I and phase II metabolites in urine and to apply the method for the identification 
of these metabolites in an authentic urine sample after administration of tramadol (II).
 To develop a micellar electrokinetic chromatography method for direct analysis of the 
glucuronides of entacapone and its (Z)-isomer in urine (III).
 To validate the micellar electrokinetic chromatography method for quantitative 
bioanalysis of the glucuronides of entacapone and its (Z)-isomer and to apply it to
urine samples of patients after administration of entacapone (IV).
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4 MATERIALS AND METHODS
The materials and methods used in the study are briefly presented in this section. The 
chemicals, other materials and instruments are listed in tables and the methods are shortly 
described. Detailed descriptions can be found in the original publications I-IV.
4.1 Chemicals, standards and materials
The chemicals, standards and materials are listed in Table 1. Chemicals were of analytical
grade and solvents of HPLC grade. Structures of the studied compounds and their pKa values 
are presented in Table 2. The pKa values were obtained from the literature or estimated with 
the Pallas 1.2 program (CompuDrug Chemistry, Budapest, Hungary).
4.2 Microsomes and recombinant human UGTs
Rat liver microsomes (RLMs) were prepared from liver homogenates of Aroclor 1254 
(polychlorinated biphenyl mixture) induced male Sprague-Dawley rats (n=5) as previously 
described [203]. The treatment of animals was approved by the local Ethical Committee for 
Animal Studies. The protein concentrations of the microsomes were determined with a 
commercial BCA Protein Assay Kit (Pierce Chemical, IL, USA). Pooled HLMs and intestinal 
microsomes (HIMs) were purchased from BD Gentest (Woburn, MA, USA) (I).
Recombinant human UGTs 1A1, 1A3-1A10, 2B4, 2B7, 2B10, 2B11, 2B15, 2B17 and 2B28 
were produced in the Faculty of Pharmacy, Division of Pharmaceutical Chemistry, University 
of Helsinki, as His-tagged proteins in baculovirus-infected insect cells [204, and references 
therein]. The relative expression levels of the UGTs were evaluated by dot-blot analyses [204,
205]. A numeric value of 1.0 was given to the expression level of UGT1A8 and the 
expression values of the other UGTs (produced in the Division of Pharmaceutical Chemistry)
were related to this value (relative expression value). Normalised activities were obtained by 
dividing the detected specific activity values by the relative expression values. A commercial 
recombinant human UGT2B15 (marked UGT2B15*) (BD Supersomes, BD Gentest, 
Woburn, MA, USA) was included in activity assays (I). This enzyme is not His-tagged, so its 
expression level could not be compared with levels of the other UGTs.
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Table 1. Chemicals, standards and materials used in the study.
Chemical / Standard Manufacturer/ supplier Notes Paper
Acetone Riedel-de Haën, Seelze, Germany EOF marker III, IV
Acetonitrile Rathburn, Walkerburn, UK LC eluent I
Alamethicin Sigma-Aldrich, St. Louis, MO, 
USA
Microsomal activator I
Ammonia solution, 25% J.T. Baker, Deventer, Holland Used in SPE eluent I, II
Ammonium acetate Merck, Darmstadt, Germany BGE II
Boric acid Merck, Darmstadt, Germany BGE III
    “       “ Riedel-de Haën, Seelze, Germany BGE IV
CAPS (3-[Cyclohexylamino]-1-
propanesulfonic acid)
Sigma, St. Louis, MO, USA BGE II
(±)-N-Desmethyltramadol
hydrochloride (M2)
Dept. of Forensic Medicine, 
Univ. of Helsinki, Finland
Standard II
(±)-O-Desmethyltramadol 
hydrochloride (M1)
Dept. of Forensic Medicine, 
Univ. of Helsinki, Finland
Standard I, II
O-Desmethyltramadol 
glucuronide (M1G)
Faculty of Pharmacy, Div. of
Pharmaceutical Chemistry, 
Univ. of Helsinki, Finland
Standard I, II
(±)-N,N-Didesmethyltramadol
hydrochloride (M3)
Dept. of Forensic Medicine, 
Univ. of Helsinki, Finland
Standard II
(±)-N,O-Didesmethyltramadol
hydrochloride (M5)
Dept. of Forensic Medicine, 
Univ. of Helsinki, Finland
Standard II
N,O-Didesmethyltramadol 
glucuronide (M5G)
Faculty of Pharmacy, Div. of 
Pharmaceutical Chemistry, 
Univ. of Helsinki, Finland 
Standard II
Dimethyl sulfoxide (DMSO) Riedel-de Haën, Seelze, Germany Solvent I
Disodium hydrogen phosphate Merck, Darmstadt, Germany BGE III
Disodium hydrogen phosphate
dihydrate
Fluka, Buchs, Switzerland Buffer constituent in
incubation matrix
I
Disodium hydrogen phosphate
dihydrate
Merck, Darmstadt, Germany BGE IV
Disodium tetraborate
decahydrate
Merck, Darmstadt, Germany BGE II–IV
Entacapone glucuronide (EG) Faculty of Pharmacy, Div. of 
Pharmaceutical Chemistry, 
Univ. of Helsinki, Finlanda
Standard III, IV
(Z)-Entacapone glucuronide
(EZG)
Faculty of Pharmacy, Div. of 
Pharmaceutical Chemistry, 
Univ. of Helsinki, Finlanda
Standard III, IV
Formic acid, 98-100% Riedel-de Haën, Seelze, Germany LC eluent I
    “          “ Merck, Darmstadt, Germany BGE II
-Glucuronidase from E. coli Boehringer, Mannheim, Germany Hydrolysing enzyme IV
-Glucuronidase  from  Helix
pomatia  (112 400 IU 
-Glucuronidase/ ml)
Sigma-Aldrich, St. Louis, 
MO, USA
Hydrolysing enzyme I
Hydrochloric acid, 37% Riedel-de Haën, Seelze, Germany Used as diluted in
SPE and to
acidify samples
I, II, IV
Hydrochloric acid (Titrisol
0.1 mol/l)
Merck, Darmstadt, Germany in SPE, conditioning IV
Magnesium chloride
hexahydrate
Merck, Darmstadt, Germany Constituent of 
incubation  mixture
I
Methanol J.T. Baker, Deventer, Holland SPE eluent, solvent I, II, IV
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Table 1, continued
Chemical / Standard Manufacturer/ supplier Notes Paper
Nitecapone glucuronide (NG) Faculty of Pharmacy, Div. of
Pharmaceutical Chemistry,
Univ. of Helsinki, Finlanda
Internal standard III, IV
Perchloric acid Merck, Darmstadt, Germany Reagent I
Potassium dihydrogen phosphate Merck, Darmstadt, Germany Buffer constituent I
D-Saccharic acid 1,4-lactone Sigma-Aldrich, St. Louis, MO
USA
Inhibitor of
-glucuronidase
I, IV
Salbutamol hemisulfate
(Vetranal)
Fluka/Sigma-Aldrich, 
Steinheim, Germany
Internal standard I
SDS (sodium dodecyl sulfate) Serva, Heidelberg, Germany Surfactant II–IV
Sodium hydroxide Merck, Darmstadt, Germany Capillary 
conditioning
III, IV
Sodium hydroxide Eka Nobel, Bohus, Sweden BGE II
Sodium dihydrogen phosphate
dihydrate 
Merck, Darmstadt, Germany BGE III, IV
(±)-Tramadol hydrochloride Dept. of Forensic Medicine,
Univ. of Helsinki, Finland
Standard II
(±)-N,N,O,-Tridesmethyltramadol 
hydrochloride (M4)
Dept. of Forensic Medicine,
Univ. of Helsinki, Finland
Standard II
N,N,O-Tridesmethyltramadol
glucuronide (M4G)
Faculty of Pharmacy, Div. of
Pharmaceutical Chemistry, 
Univ. of Helsinki, Finland 
Standard II
Uridine-5’-diphosphoglucuronic 
acid triammonium salt
Sigma-Aldrich, St. Louis,
MO, USA
Co-substrate I
Uridine-5’-diphosphoglucuronic 
acid trisodium salt
Sigma-Aldrich, St. Louis, 
MO, USA
Co-substrate I
Water (Milli-Q purified) Millipore, Molsheim, France Solvent I–IV
Other material Producer Notes Paper
Fused silica capillaries Composite Metal Services,
Hallow, Worcs. UK
CE capillaries II-IV
Microcon-50 ultrafiltration
device 
Amicon, Beverly, MA, USA Ultrafiltration
NMWL 50 000 Da
IV
Millex-HV membrane filter 
0.45 μm
Millipore, Japan Sample filtration II–IV
Tracer membrane filter 0.45 μm Filtration of solutions II
Acrodisc 13 filter 0.45 μm Gelman Filtration of solutions III, IV
aPrepared as described in ref. [109]
4.3 Urine samples
Blank, drug-free urine (control urine) was collected from a healthy volunteer (II-IV). Urine 
that contained tramadol metabolites (TR-U) was collected 0–12 h after tramadol 50 mg 
(Tramal 50 mg, Orion Pharma, Espoo, Finland) intake (II). In investigations of entacapone
metabolites, authentic patient urine samples were from clinical trials and included drug-free 
pre-dose urine samples and samples collected 0–12 h after an oral (200 mg) or intravenous
(i.v.) (25 mg) dose of entacapone (IV). Spiked urine samples were used for method 
development, and a patient urine sample from the clinical study was used to demonstrate the 
suitability of the method (III).
39 
 
4.4 Methods and instrumentation
The methods and conditions used in LC and CE separations are listed in Table 3. The LC and
UPLC instruments and the mass spectrometer used in the first study (I) are described in 
Sections 4.4.1, 4.4.2 and 4.4.5, while the methods and instruments employed in structural 
characterisation of M1Gs are described in Section 4.4.3. A Beckman P/ACE 2200 CE 
instrument (Beckman Fullerton, CA, USA) controlled with Beckman P/ACE Station Version 
1.21 (II) and System Gold software (III, IV) was used in studies II-IV.
Table 2. Structures of the studied compounds.
Structure Compound  (Abbreviation*)
(Paper)
MW pKa 
Tramadol metabolites
O-methylated
R1          R2  
H
N
H 3 CO
OH
R 1
R 2
 
CH3       CH3
CH3       H
H           H
 
 
(±)-Tramadol   (TR)             (II)
(±)-N-Desmethyltramadol 
(M2)                                     (II)
(±)-N,N-Didesmethyl-
tramadol  (M3)                     (II)
263
249
235
8.3       [84]
9.4       [206]
11.0a
10.7a
O-demethylated (phenolic)         R1          R2   ~10a
(phenolic OH)
H
N
HO
OH
R 2R 1
 
CH3       CH3
CH3       H
H           H
(±)-O-Desmethyltramadol    
(M1)                                     (II)
(±)-N,O-Didesmethyl-
tramadol  (M5)                     (II)
(±)-N,N,O-Tridesmethyl-
tramadol  (M4)                     (II)
249
235
221
9.8a
11.0a
10.7a
glucuronides R1          R2  ~3.2 (-COOH)
              [25]
O O
N
H
OH
COOH
OH
OH
OH
R 1
R 2
  
CH3    CH3
CH3     H
H        H
 
Glucuronide of 
O-Desmethyltramadol  (M1G)
                                          (I, II)
Glucuronide of 
N,O-Didesmethyltramadol  
(M5G)                                  (II)
Glucuronide of 
N,N,O-Tridesmethyl-
tramadol   (M4G)                  (II)
425
411
397
9.8a
11.0a
10.7a
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Table 2, continued
Structure Compound (Abbreviation*)
(Paper)
MW pKa
Entacapone glucuronides
O O
N
O
OH
OH
COOH
OH
NO 2HO
CN
 
 
 
 
Glucuronide of entacapone
(EG)                              (III, IV)
 
 
 
481
 
~3.2 (-COOH)
             [25]
4.1 
(phenolic OH)
             [103]
O O
N
O
OH
OH
COOH
OH
HO NO 2
CN
 
Glucuronide of the (Z)-isomer 
of entacapone   (EZG)
                                      (III, IV)
481
~3.2  (-COOH)
             [25]
4.2
(phenolic OH)
             [103]
 
 
* The abbreviations M1–M5 are in common use for phase I metabolites of tramadol [15, 91, 93, 98,
175]. In this study the glucuronidated metabolites of tramadol (M1G, M4G and M5G) are collectively 
also called “tramadol glucuronides” and the glucuronides of entacapone and its (Z)-isomer
“entacapone glucuronides”. The abbreviation Glu-1 is used for the 1S,2S-O-desmethyltramadol 
glucuronide and Glu-2 for the 1R,2R-diastereomer. aThe pKa values are estimated with the Pallas 1.2 
program.
4.4.1  Enzyme-assisted synthesis and purification of O-desmethyltramadol glucuronides (I)
Reference compounds were obtained by carrying out enzymatic synthesis of M1Gs with
RLMs (I). The incubation mixture consisted of 1.5 mM (±)-M1 (in 400 μl of DMSO), 5 mM 
D-saccharic acid 1,4-lactone, 5 mM MgCl2, 20 mg of pooled RLMs and 10 mM UDP-GA in
50 mM Na-K-phosphate buffer (pH 7.4) in a total volume of 20 ml. The concentration of 
DMSO in incubation mixture was 2% (v/v). The addition of UDP-GA started the reaction,
which was carried out in a water bath at 37 ºC with magnetic stirring for 20 h. The reaction 
vessel was then transferred to an ice bath, and 2 ml of ice-cold 4 M perchloric acid was added 
to precipitate the enzyme. The mixture was centrifuged (26700g, 10 min, 6 ºC) and the 
supernatant was collected and purified by cation exchange SPE that selectively retained basic 
compounds (Table 4). The extract that contained the two product glucuronides and the 
aglycone was fractionated with an Agilent 1100 Series HPLC equipped with a fraction 
collector (Agilent Technologies, Waldbronn, Germany; ChemStation software) under acidic  
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Table 3. Methods and conditions used in the separation of tramadol and entacapone glucuronides.
Methods Purpose Column / Capillary Eluent/ BGE Paper
HPLC/UV
	 272 nm
HPLC/DAD
	 210, 272 nm
fluorescence
Ex 269,
Em 310 nm
UPLC
/
(PDA)
ESI-MS
and 
ESI-MS/MS
Fractionation of the 
diastereomeric M1
glucuronides
Purity tests and
stability tests of the 
diastereomeric M1 
glucuronides
Structure 
characterisation
Enzyme activity 
assays 
Kinetic studies
Determination of the 
yield
HP Hypersil BDS C18
(5 μm, 250 x 4.0 mm)
(Agilent Technologies, 
USA)
Zorbax Eclipse Plus C18
(5 μm, 250 x 4.6 mm)
(Agilent Technologies, 
USA)
Acquity UPLC BEH C18
(1.7 μm, 50 x 2.1 mm),
(Waters)
0.1% HCOOH,
pH 2.66,  ACN  
(gradient)
0.1% HCOOH,
pH 2.66
87.4% H2O,
MeOH  12.5%,
(isocratic)
0.1% HCOOH,
pH 2.66
ACN  
(gradient)
I
CE/UV
	 200 nm
CE/UV
	 200 nm
MEKC/UV
	 200 nm
Separation of the 
diastereomeric 
glucuronides of 
tramadol
Separation of 
tramadol metabolites
Separation of the 
diastereomeric 
glucuronides of
tramadol
Fused silica capillary
50 μm  i.d., 375 μm o.d.
50/ 57 cm  (Leff /Ltot)
17 kV; inj. 5 s + 1 s
at 0.5 psi
Fused silica capillary
50 μm  i.d., 375 μm o.d.
40/ 47 cm (Leff /Ltot)
9 kV; inj. 3 s 
at 0.5 psi
Fused silica capillary
50 μm  i.d., 375 μm o.d.
40/ 47 cm (Leff /Ltot)
13 kV; inj. 10 s
at 0.5 psi
10 mM 
ammonium acetate, 
100 mM
HCOOH,
pH 2.75
65 mM disodium 
tetraborate,
162.5 mM NaOH,
pH 10.65
25 mM disodium
tetraborate, 60 mM 
NaOH , 70 mM 
SDS, pH 10.45
II
MEKC/UV
	 335 nm
Optimisation of the 
separation for the 
diastereomeric 
glucuronides of
entacapone
Fused silica capillary
75 μm  i.d., 375 μm o.d.
60/ 67 cm (Leff /Ltot)
15 kV; inj. 8 s
at 0.5 psi 
25 mM phosphate, 
50 mM borate, 20 
mM SDS, pH 7
    III
MEKC/UV 
	 335 nm
Validation and 
quantification of
the diastereomeric 
glucuronides of 
entacapone
Fused silica capillary
75 μm  i.d., 375 μm o.d.
60/ 67 cm (Leff /Ltot)
15 kV; inj. 8 s
at 0.5 psi
25 mM phosphate,
50 mM borate, 20 
mM SDS, pH 7 
    IV
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Table 4. Solid-phase extraction procedures used for clean-up and concentration.
Cartridge Conditioning Sample
loading
Washing Elution Paper
Oasis MCX
150 mg/ 6 ml 
(Waters, Milford,
MA, USA)
3 ml of MeOH
3 ml of H2O
Acidic
supernatant 
of synthesis 
mixture 
(5 ml/ cartridge)
4 ml of 
0.05 M HCl
2 x 3.5 ml of 
0.5% ammonium 
hydroxide in
H2O–MeOH
(5:95 v/v) 
I
Oasis MCX
30 mg/ 1 ml
(Waters, Milford,
MA, USA)
1 ml of MeOH
1 ml of H2O
1 ml of urine 
acidified
with 100 μl of 
1 M HCl
1 ml of
0.1 M HCl 
and 
1 ml of MeOH
1 ml of 0.25%
ammonium 
hydroxide in 
H2O–MeOH
(5:95 v/v)
II
Sep-Pak Vac 
C18
100 mg/1 ml
(Waters, Milford,
MA, USA)
1 ml of MeOH
1.5 ml of
0.05 M HCl  
containing 2% 
of MeOH
1 ml of urine
acidified with 
160 μl of 
1 M HCl
1 ml of
2 mM HCl
and 1 ml of 
MeOH–H2O
(5:95 v/v)
1.25 ml of 
MeOH–H2O
(55:45 v/v)
IV
mobile phase conditions (pH 2.66) and gradient elution in RPLC/UV (Table 3). The eluents 
were 0.1% HCOOH (aq.) (A) and acetonitrile (B) and the gradient profile was (0–15 min) B: 
7.5–15%, (15–21 min) B: 15%, (21–22 min) B: 15–7.5% with an equilibrium time of 8 min. 
The flow rate was 0.8 ml/min. The separated M1Gs were collected either to separate fractions 
I (Glu-1, tR 10.3 min) and II (Glu-2; tR 10.8 min) for characterisation or as one fraction for use 
as reference standard. The isolated fractions were rotary evaporated, lyophilised or dried in 
vacuum (Genevac HT-4 series II evaporator, Ipswich, UK). The purification and fractionation 
is described in more detail in the original publication I.
4.4.2  Purity and stability tests of O-desmethyltramadol glucuronides (I)
For assessment of the purity and stability of M1Gs, the products (separate fractions I and II or 
the combined fraction) were dissolved in water. Purity and stability were determined with an 
Agilent 1100 Series HPLC (Agilent Technologies, Waldbronn, Germany) with both 
fluorescence (Ex 269, Em 310 nm) and diode array (	 210, 272 nm) detection with use of the 
column presented in Table 3 (I). Isocratic elution mode (87.4% H2O, 0.1% HCOOH and
12.5% MeOH) was used, with a flow rate of 0.8 ml/min and analysis time of 50 min. The 
method provided baseline resolution of the analytes. The purity, as a percentage, was 
calculated as peak area ratios (Aglucuronides/ Atotal of all peaks) at 210 nm. The stability of the M1G
standard solution (750 μM) was determined by keeping a test sample in a dark vial at 22°C 
for 24 h.
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4.4.3 Structural characterisation of O-desmethyltramadol glucuronides (I)
The mass spectrometric structural characterisation of M1Gs (Glu-1 and Glu-2; Section 4.4.1)
was carried out by UPLC/ESI-MS and MS/MS (Table 3) in positive and negative ion modes
(Section 4.4.5). In NMR structure characterisation the 1H spectrum of Glu-1 was measured
with a Varian Mercury Plus 300 MHz spectrometer (Varian, Palo Alto, CA, USA) and the 1H
spectrum of Glu-2 and nuclear Overhauser effect spectroscopy (NOESY) spectra of both 
glucuronides with a Varian Unity INOVA 600 MHz spectrometer (Varian, Palo Alto, CA, 
USA) equipped with a cryoprobe (I). For comparison, 1H spectrum was measured for M1 as 
well. DMSO-d6 was used as solvent and the 1H chemical shifts were referenced to DMSO 2.5 
ppm.
4.4.4 Enzyme activity assays (I)
Sixteen recombinant human UGTs were initially screened for M1 glucuronidation activity
using high UDP-GA concentration (10 mM) and very long incubation time (16 h) (I). The 
actual activity screening was carried out with selected UGT enzymes (1A1, 1A3, 1A6-1A10, 
2B4, 2B7, 2B17 and 2B15*) and alamethicin-activated HLMs and HIMs as described in 
detail in publication I. The 60 μl reaction mixtures contained 0.5 mM (±)-M1, 2% (v/v) of
DMSO, 5 mM UDP-GA, 5 mM MgCl2 and 60 μg protein in 50 mM Na-K-phosphate buffer 
(pH 7.4). The samples were incubated at 37 °C for 2 h, whereafter the reactions were 
terminated with 6 μl of ice-cold 4 M perchloric acid. After centrifugation (16100g, 10 min, 22 
°C), an aliquot (50 μl) of the supernatant was transferred to a vial that contained the dried-
down IS (salbutamol sulfate, 4.8 μM). The incubations were carried out in triplicate, except 
for the negative controls, which were single samples. The formed diastereomeric glucuronides 
were analysed as described in Section 4.4.5.
Kinetic analyses to follow the formation of M1Gs were carried out with UGTs 1A8 and 2B7
(I). Before the assays the incubation conditions were optimised for both enzymes so that the 
product formation was linear with respect to protein concentration and time. The substrate in 
these studies was (±)-M1 and the concentrations ranged from 50 to 4000 μM of racemic 
compound (i.e., 25 to 2000 μM of each enantiomer). The samples were prepared in triplicate,
except the highest concentration samples, which were in duplicate. Control samples without 
UDP-GA were included in the sample set. Otherwise the reactions (60 μl) were performed in 
the same manner as the activity assays and analysed as described in Section 4.4.5 and the 
publication I.
The velocity data obtained from the enzyme kinetic analyses were normalised (Section 4.2),
and kinetic models were fitted using GraphPad Prism (version 4.03 for Windows; GraphPad 
Software Inc., San Diego, CA, USA). The three models were:
44 
 
1. The Michaelis-Menten equation [v = Vmax x S/(Km + S)], where v is the initial velocity 
of the reaction, S is the substrate concentration, Vmax is the maximal velocity and Km is 
the substrate concentration at 0.5 Vmax.
2. The Hill equation [v = Vmax x Sh/(Sh50 + Sh)], where S50 is the substrate concentration 
resulting in 50% of Vmax and h is the Hill coefficient.
3. The substrate inhibition equation [v = Vmax x S/(Km + S + S2/Ki)], where Ki is the 
constant describing the substrate inhibition interaction.
An Eadie-Hofstee plot (v vs. v/S) was drawn for visual inspection. The best kinetic model was
chosen by evaluating r2 values and observing the randomness of the residuals and standard 
errors of the estimates.
4.4.5 Analysis of O-desmethyltramadol glucuronides by ultra performance liquid 
chromatography/ electrospray–mass spectrometry (I)
UPLC/ESI-MS techniques (Acquity UPLC, Waters Corp., Millford, MA, USA coupled with 
quadrupole time-of-flight mass spectrometer, Q-TOF Micro, Waters/ Micromass, Manchester, 
UK; MassLynx 4.1 software) were used in structural characterisation, activity experiments
and indirect analysis of M1 glucuronides (Table 3) (I). The eluents in the separations were 
0.1% HCOOH (A) and acetonitrile (B). In structure characterisation studies the gradient 
conditions were (0–4 min) B: 5–85%, (4–4.5 min) B: 85–5% with an equilibrium time of 2.5
min in positive ion mode and (0–2 min) B: 10–90%, (2–4 min) B: 90–10% with an
equilibrium time of 3 min in negative ion mode. The eluent flow rates in positive and negative 
modes were 1.0 and 0.7 ml/min, respectively. For these studies the dried glucuronides (Glu-1
and Glu-2) were dissolved in methanol–water (2:5 v/v) (I).
In structure characterisations the mass spectrometer was operated in positive and negative ion 
modes. In positive ion mode the ion source voltage was set at 3000 V and the source 
temperature at 120 °C. The corresponding settings in negative ion mode were – 2000 V and 
150 °C. In MS/MS experiments the protonated or deprotonated molecule of M1Gs was 
selected as a precursor ion. The analytical conditions and instrumental settings are presented
in detail in publication I. The analytes were also detected with a photodiode array (PDA) 
detector and, their UV spectra were recorded from 200 to 400 nm. 
UPLC/ESI-MS, employing RPLC with the same eluents A and B as above, was also used to 
analyse samples from activity experiments (Table 3) (I). Under acidic conditions both the 
glucuronides and the IS (salbutamol sulfate) were ionised in liquid phase. The gradient profile 
was (0–4 min) B: 2–7%, (4–4.5 min) B: 7–85%, (4.5–5 min) B: 85–2% with equilibrium time 
of 2 min. The flow rate was 0.7 ml/min. Contamination of the ion source was prevented by 
directing the early eluting salts (0–1.1 min) to waste with a six-port switching valve 
(Rheodyne LLC, Robnert Park, CA). The flow to MS was compensated with 5% acetonitrile–
water with the aid of an auxliliary pump. The injection volume was 2 μl. MS analyses were 
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performed by monitoring the protonated molecules of M1G (m/z 426) (Glu-1 tR 2.40 min, 
Glu-2 tR 2.59 min) and salbutamol (m/z 240) (tR 1.48 min). The UPLC/ESI-MS method was 
validated with respect to linearity, accuracy, precision, LOD, LOQ and analyte stability 
(described in Section 4.4.2) (I). The same method was used in the indirect analysis of the 
hydrolysed M1G samples, but then, the protonated molecule of liberated M1 (m/z 250) (tR
3.38 min) was monitored. IS was not used in the indirect analysis.
4.4.6 Separation of tramadol metabolites and diastereomeric glucuronides by capillary 
electromigration techniques (II)
Three methods that relied on capillary electromigration techniques with UV detection were 
developed to analyse the free (M1, M2, M3, M4 and M5) and glucuronidated (M1G, M4G 
and M5G) metabolites of tramadol (Table 3) (II). CE was applied to separate tramadol and all 
the above-mentioned metabolites. To optimise the pH, the electrophoretic mobility of analytes 
was investigated in disodium tetraborate and 3-(cyclohexylamino)-1-propanesulfonic acid 
(CAPS) electrolytes in the pH range 9.8–10.8. The effect of concentration was studied in 
disodium tetraborate electrolyte solutions (30–65 mM) at pH 10.65 (pH adjusted with sodium 
hydroxide). LODs for the analytes as well as the repeatability of the method were determined
under the optimised conditions (Table 3). The applicability of the CE/UV method to identify 
tramadol and its main metabolites in human urine was tested with an authentic urine sample 
collected for 12 h after administration of a single dose (50 mg) of tramadol. After SPE 
purification (Table 4.) and 5-fold concentration, the test sample was compared with a pre-
dose urine sample spiked with tramadol metabolites. Furthermore, migration behaviour of the 
three glucuronides (M1G, M4G and M5G) was examined at low pH conditions in ammonium 
acetate (10 mM) formic acid (100 mM) BGE (pH 2.75) and also in basic MEKC conditions
(pH 10.45) using 25 mM of disodium tetraborate, 60 mM of sodium hydroxide and 0–90 mM 
of SDS as the BGE.
4.4.7 Separation of the glucuronides of entacapone and its (Z)-isomer by micellar 
electrokinetic chromatography (III, IV)
With the aid of reference glucuronides synthesised in the laboratory [109], a MEKC/UV
method was developed for separation of the glucuronides of entacapone and its (Z)-isomer 
(EG and EZG) in urine (III). Composition of the BGE was optimised in terms of electrolytes, 
pH (in the range of 5–8), concentration (phosphate 15–25 mM and borate 36–50 mM) and 
SDS concentration (20–60 mM). Nitecapone glucuronide (NG) was chosen as the IS. The 
suitability of the method for quantitative analysis of EG and EZG in human urine was 
evaluated in validation studies (IV). The following analytical parameters were investigated:
identity of the analytes, selectivity, LOQ, linearity and range, within-day precision, extraction 
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recovery and between-day precision and accuracy. EOF stability was investigated both 
within-day and between-days. Analyte stability during the analysis was tested as well.
Uncoated fused-silica capillaries (Table 3) were used throughout the study (II-IV). The 
samples were hydrodynamically injected (3–10 s with pressure 0.5 psi (~3.45 kPa) at the 
anodic end of the capillary and detected by UV (Table 3) (II-IV). Acetone (3% v/v aqueous 
solution) (III, IV) or methanol–water (stock solutions of analytes were prepared in methanol–
water, 50:50 v/v) (II) was used as an EOF marker. The electroosmotic hold-up time (teo)
(detected as a negative peak) was used as the reference peak when relative migration times 
were determined (analyte migration time (tm)/ teo).
4.4.8 Quantitative analyses (I, IV)
The calibration samples for quantitative analysis were prepared in an incubated blank matrix 
(I) or in blank urine (IV). All samples contained IS. In study I the dried-down IS (salbutamol 
sulfate) was added after sample preparation (4.4.4), while in study IV the IS solution (NG,
concentration in samples 15 μg/ml) was added before SPE. Linearity of the methods was 
assessed with calibration samples of seven to ten different concentrations, one to six samples
per concentration (I, IV). Calibration samples were prepared for every sample set (I, IV). The 
calibration curves were constructed by plotting peak area (A) ratios of the analytes to IS
(Aanalytes/ AIS) as a function of the concentration of the analytes (I). Corrected peak areas were
used in study IV. External standard method with duplicate samples of eight concentrations
was employed in the analysis of hydrolysed M1G samples (I). The methods were either 
partially (I) or fully (IV) validated.
4.4.9 Sample preparation procedures (I-IV)
Before instrumental analyses, different sample preparation methods were used to clean up or 
concentrate the samples. Protein precipitation and centrifugation are described in Sections
4.4.1 and 4.4.4 (I). SPE procedures are summarised in Table 4 (I, II, IV). Before CE analysis 
all samples were passed through 0.45 μm filters (Table 1) (II-IV) and shortly sonicated (III-
IV). In study IV, samples were protected from light during handling to avoid isomerisation of 
the analytes.
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 -glucuronidase was used to identify the 
compounds in an authentic urine sample as glucuronides of entacapone (IV). Before the 
hydrolysis a urine sample spiked with EG and EZG, an authentic urine sample (see Section 
4.3) and a pre-dose urine sample were subjected to SPE. The hydrolysis was then carried out 
by treating the aqueous extracts with -glucuronidase (from Escherichia coli) and incubating 
them in 12.5 mM phosphate buffer (pH 6.85) at 37 °C for 3 h in the absence and presence of 
D-saccharic acid 1,4-lactone. Control samples, in which the enzyme solution was replaced 
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with phosphate buffer, were incubated in the same way. During the incubation, aliquots were 
taken from the samples at 20 min, 1 h and 3 h. Before the MEKC analysis, ultrafiltration of 
the hydrolysed samples was carried out to remove enzyme proteins larger than MW 50 000 
(Table 1). Details are presented in paper IV. Hydrolytic cleavage of the M1 glucuronides with 
-glucuronidase was also utilised in the determination of the synthesis yield (I). The 
hydrolysis was performed by incubating two similarly prepared M1G samples and two M1
samples in parallel in 0.1 M sodium acetate buffer (pH 5) at 37 °C for 8 h in the presence of 
-glucuronidase (from Helix pomatia).
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5 RESULTS AND DISCUSSION
The main results of the work are summarised in this chapter. Details can be found in the 
original publications I-IV. Stereoselective biosynthesis of O-desmethyltramadol (M1) 
glucuronides, characterisation of the product glucuronides and the results of enzyme reactions 
analysed by UPLC/ESI-MS technique are presented and discussed, after which the
development and optimisation of CE/UV methods for the separation of tramadol and its 
metabolites and the glucuronides of entacapone in urine are described. The last section reports 
and discusses the validation of the MEKC/UV method and analyses of patient urine samples.
5.1 Enzyme-assisted synthesis of O-desmethyltramadol glucuronides (I)
Small amounts of three tramadol glucuronides (M1G, M5G and M4G) were enzymatically 
synthesised in our laboratory earlier (Division of Pharmaceutical Chemistry). RLMs were 
used as the UGT source since glucuronidation was known to be an important metabolic 
pathway for tramadol in rats [91, 92]. The amounts formed were insufficient for NMR-based 
structural characterisation, however. It was considered important, therefore, to optimise the 
synthesis and characterise the products. (±)-O-Desmethyltramadol (M1), the most active 
metabolite of tramadol, was chosen as starting material (I).
Incubation conditions were optimised before the larger-scale biosynthesis of M1Gs. Rat and 
pig liver microsomes were tested as the enzyme source, and concentrations of the substrate 
(±)-M1 (0.250–4 mM), co-substrate UDP-GA (3–10 mM) and microsomal protein (0.5–4
mg/ml) were evaluated. RLMs catalysed the formation of two glucuronides, which were 
detected in the LC/UV chromatograms without interfering peaks (Fig. 8). Greater interference 
was observed in the corresponding chromatograms of reactions catalysed by pig liver 
microsomes and RLMs were therefore selected as the catalyst, with protein concentration of 1 
mg/ml. Substrate inhibition was not observed within the concentration range tested, and 
substrate concentration of 1.5 mM was chosen for the biosynthesis. The concentration of co-
substrate appeared to be important for the optimisation: increase in UDP-GA concentration 
from 5 to 10 mM almost doubled the glucuronide production, so the highest tested UDP-GA 
concentration of 10 mM was chosen to maximize the yield. The effect of incubation time was 
followed up to 30 h. Formation of glucuronides increased linearly up to 20 h, whereafter it did 
not increase even though (±)-M1 was still present. On this basis, incubation time of 20 h was 
chosen.
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Figure 8. HPLC separation of (±)-O-desmethyltramadol (M1) and its diastereomeric O-glucuronides
(tR10.3 and 10.8 min) using gradient elution and UV detection at 272 nm. (±)-M1 (1.5 mM) was 
incubated at 37 °C with rat liver microsomes (1 mg/ml) and UDP-GA (10 mM) for 20 h. Conditions as 
in Table 3. Injection volume 25 μl.
M1 glucuronides were biosynthesised and purified as described in Section 4.4.1. The amounts 
of the isolated M1 glucuronides, named in their retention order as Glu-1 and Glu-2, were c. 3 
mg and c. 1 mg, respectively (I). The glucuronides were characterised as diastereomers as 
described in Section 5.2. The yields of Glu-1 and Glu-2 were 54 and 22% (calculated on the 
basis of one enantiomer) (I). Baseline resolution of the glucuronides was not reached with the 
LC method used for fractionation, and Glu-2 contained 5.2 % of Glu-1 (Fig. 8). The results 
showed that glucuronide formation catalysed by RLMs was clearly stereoselective.
Another batch of M1 glucuronides was synthesised to obtain a reference standard for activity 
screening and kinetic studies. After verification the glucuronides were collected as a
combined fraction (I). The yield was 6.5 mg: 51% of the theoretical yield, as determined 
indirectly by enzymatically hydrolysing a small aliquot of the product. The indirect analysis 
method was chosen since the presence of 2.5 mol of crystal water has been reported for the 
chemically synthesised M1Gs [117]. The relative amounts of Glu-1 and Glu-2 were 78% and 
22%, respectively (I). The final purity of the product was 91.5% determined at 210 nm (see 
Section 4.4.2). The aqueous solution of M1G standard was stable when stored at 22 °C for 24 
h (I).
5.2 Structural characterisation of O-desmethyltramadol glucuronides (I)
The collected fractions I and II were identified as M1 glucuronides by LC-MS analysis (I). A 
rapid UPLC separation with steep gradient was employed (see Section 4.4.5). The mass 
spectra of both fractions showed abundant protonated molecules ([M+H]+) at m/z 426 in 
positive ion mode and deprotonated molecules ([M-H]) at m/z 424 in negative ion mode 
indicating that the fractionated compounds were M1 monoglucuronides. The produt ion 
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spectra of [M+H]+ and [M-H] revealed that the main product ions were m/z 250 [M+H-Glu]+
and m/z 232 [M+H-Glu-H2O]+ in positive ion mode and m/z 248 [M-H-Glu] , m/z 175 [Glu-
H] and m/z 113 [Glu-H-H2O-CO2] in negative ion mode confirming the presence of 
glucuronide moiety in the structures. The close similarity of the MS/MS spectra—as well as 
the UV spectra—suggested that the glucuronides were diastereomers. The site of 
glucuronidation among the three possible sites could not be determined on the basis of these 
mass spectrometric studies. 
Further structural information on the M1 glucuronides was obtained by NMR spectroscopy
(I). In the 1H spectra of Glu-1 and Glu-2 the signal at ca. 4.82 ppm belongs to glucuronic acid 
proton H1 (Fig. 9). The signal appeared as a doublet with a coupling constant 3JH1,H2 of 7.5 
Hz, which is a typical value 
-anomeric glucuronic acid [207] and verifies the glycosidic 
linkage to be . In addition, the site of glucuronidation could be established. Comparison of
the one-dimensional 1H spectra of M1 and M1Gs showed the aromatic signals to shift upon 
glucuronidation, which indicates that the glucuronides are phenolic. The largest chemical shift 
change, 0.26 ppm in Glu-1 and 0.23 ppm in Glu-2, occurred for proton 6’ (Fig. 9). A 
comparable shift change has been reported for the aromatic protons in phenolic O-
glucuronides of dobutamine [112]. The structure of the glucuronides was confirmed with
Figure 9.  NOESY spectrum of 1S,2S-O-desmethyltramadol glucuronide (1S,2S-M1G). Inter-
glycosidic NOE correlations detected between glucuronic acid proton H1 (4.82 ppm) and aromatic 
protons 2’ (~7.12 ppm) and 6’ (6.9 ppm) confirmed the compound to be phenolic O-glucuronide of 
M1.
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NOESY, which shows the couplings of protons through space. NOESY spectra revealed inter-
glycosidic NOE correlations between glucuronic acid proton H1 and the aromatic protons 2’ 
and 6’ located ortho to the glucuronidated hydroxyl (Fig. 9). This confirmed that the collected 
fractions I (Glu-1) and II (Glu-2) were phenolic glucuronides and diastereomers. Since other 
NOE couplings were not detected, these experiments could not solve the stereochemistry of 
the M1Gs. The biotransformation of racemic tramadol is shown in Fig. 10.
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Figure 10. Biotransformation of racemic tramadol to O-desmethyltramadol O-glucuronide (M1G)
diastereomers.
The final step in the characterisation of glucuronides was to identify the M1Gs as 1R,2R- and 
1S,2S-diastereomers (I). The identity was deduced on the basis of the capillary electrophoretic 
migration order as reported earlier [165, 199 and paper II]. Under acidic CE conditions the 
1S,2S-diastereomer of M1G migrated before its 1R,2R-counterpart [165, 199], and under
corresponding conditions in reactions catalysed by RLMs the peak of the first migrating 
1S,2S-diastereomer was larger than that of the 1R,2R-diastereomer [paper II]. The order of 
elution in LC under acidic conditions is the same (Fig. 8), so it follows that the larger, first 
eluting peak (Glu-1) represents the 1S,2S-diastereomer and the smaller, later eluting peak 
(Glu-2) the 1R,2R-diastereomer.
In summary, two glucuronides were produced from (±)-M1 in enzyme-assisted synthesis with
RLMs as the catalyst. The products, separated and isolated by HPLC, were identified as 
glucuronides by LC-MS and MS/MS on the basis of typical product ions. The position of the 
glycosidic linkage was determined by investigating the chemical shifts of aromatic protons in
1H NMR spectroscopy. The NOE correlations detected between the anomeric proton and the 
specific aromatic protons verified that the conjugation site was the phenolic hydroxy group.
The final step defining the stereochemistry of the diastereomeric M1Gs was accomplished on 
the basis of earlier studies.
i
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5.3 Glucuronidation of O-desmethyltramadol by UGTs and human tissue microsomes
(I)
Screening assays were carried out to identify the human UGT enzymes that catalyse M1 
glucuronidation (I). In addition, the activity of human liver and intestinal microsomes was 
examined. Special attention was paid to the stereoselectivity of the reactions since 
glucuronidation of (±)-M1, (±)-M4 and (±)-M5 by RLMs had revealed stereoselectivity (I,
II). 
The results of the screening experiments are presented in Table 7. On the basis of initial 
screening tests, eleven enzymes, namely the UGTs 1A1, 1A3, 1A6-1A10, 2B4, 2B7, 2B15* 
and 2B17, were selected for actual activity assays carried out under different conditions (see 
Section 4.4.4) (I). The assays showed measurable (±)-M1 glucuronidation activity (Table 7) 
Table 7. Glucuronidation rates of (±)-O-desmethyltramadol (M1) in activity assays (2 h), actual and 
normalised values ± SD.
UGT/ microsomes
Glucuronidation rates
actual and normalised values (pmol/mg/min)
O-Desmethyltramadol glucuronide
1S,2S-Diastereomer 1R,2R-Diastereomer
1A1 n.d.a n.d.
1A3 n.d. n.d.
1A6 n.d. n.d.
1A7 n.d. 3.1 ± 0.12    (0.5 ± 0.02)b
1A8 n.d. 14.2 ± 1.9
1A9 n.d. 7.8 ± 0.8     (6.7 ± 0.7)b
1A10 n.d. 3.9 ± 0.25   (6.9 ± 0.4)b
2B4 Detectable (< LOQ) n.d.
2B7 5.7 ± 0.6   (13.8 ± 1.4)b 3.8 ± 0.07    (9.3 ± 0.2)b
2B17 n.d. n.d.
Glucuronidation rates
(not normalised) (pmol/mg/min)
2B15* c Detectable (< LOQ) 3.9 ± 0.3
HLMs 62.4 24.6
HIMs 6.0 ± 1.2 5.7 ± 0.7
an.d.   Glucuronide formation not detected.
bThe normalised glucuronidation rates are presented in brackets.
cUGT2B15* was of commercial origin and its expression level was unknown. The normalised 
glucuronidation rate for this UGT could not be determined.
only for UGTs 1A7–1A10, 2B7 and 2B15*. Both screening tests also revealed a considerable 
degree of stereoselectivity in these reactions, and 1R,2R-M1 seemed to be the preferred 
substrate. The UGTs 1A7–1A10 were strictly enantiospecific and glucuronidated only the 
1R,2R-M1. UGT2B7, on the other hand, displayed broader receptivity and glucuronidated 
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both M1 enantiomers, with preference for the 1S,2S-M1. Likewise, UGT2B15* catalysed the 
formation of both M1 glucuronides but favoured the 1R,2R-enantiomer. Additionally, 
UGT2B4 was able to catalyse 1S,2S-M1 glucuronidation, but its activity was low. The most 
active UGT isoforms in this study were the UGTs 1A8 and 2B7. HLMs—like RLMs—
glucuronidated both enantiomers of M1 but exhibited preference for the 1S,2S-enantiomer. 
Glucuronidation catalysed by HIMs, on the other hand, yielded both M1 glucuronides at 
almost equal, but low rates (Table 7, Fig. 11). The extracted ion chromatograms of [M+H]+
(m/z 426) of M1-O-glucuronides formed in these reactions are presented in Fig. 11 (I).
Figure 11. Analysis of activity for samples screened by positive ion mode UPLC/ESI-MS (I).
Extracted ion chromatograms ([M+H]+, (m/z 426) of O-desmethyltramadol glucuronides formed in 
reactions catalysed by UGTs 1A8, 2B7 and microsomes of human liver and intestine. In the case of 
UGT1A1 catalysed reaction, no glucuronide formation is detected in the ion chromatogram.
Conditions as in Table 3.
An interesting finding from the initial screening tests was that UGT1A4 probably catalyses
the formation of N+-glucuronides at low rates, since tiny peaks corresponding to mass m/z 426 
appeared at tR 2.85 and 3.01 min (I, Fig. 4). No peaks were detected at the retention times of 
the M1-O-glucuronide diastereomers (tR 2.40 and 2.59). The capability of human UGT1A4 to 
catalyse aliphatic tertiary amine glucuronidation is well known [57]. The presence of M1-N-
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glucuronides in urine samples after tramadol treatment has not, however, been reported earlier
[93]. In view of the very low glucuronidation rate this finding of N+-glucuronides was not 
pursued.
The most active UGTs, 1A8 and 2B7, were selected for kinetic studies (I). Glucuronidation of 
1R,2R-M1 by UGTs 1A8 and 2B7 followed Michaelis-Menten kinetics (Table 8), while 
glucuronidation of 1S,2S-M1 by UGT2B7 was best described by the Hill equation (h = 1.18) 
Table 8. Kinetic constants (± SE) for 1S,2S- and 1R,2R-O-desmethyltramadol (M1) glucuronidation 
by recombinant human UGTs 1A8 and 2B7.
1S,2S-O-desmethyltramadol 1R,2R-O-desmethyltramadol
UGT S50 (mM) Vmax (pmol/mg/min) Km (mM) Vmax (pmol/mg/min)
1A8c 1.2 ± 0.23a 81.6 ± 8.8
2B7c 1.84 ± 1.2b 98.6 ± 38.2 4.6 ± 2.0a 62.2 ± 20.6
aMichaelis-Menten equation, bHill equation (h = 1.18), cSaturating concentration not reached with the 
highest substrate concentration tested (2 mM/ enantiomer). 
since the curvature of the Eadie-Hofstee plot suggested autoactivation kinetics (Fig. 12, Table 
8). The kinetic assays revealed relatively high Km and S50 values for 1R,2R-M1 and 1S,2S-M1 
glucuronidation, respectively, which indicates that both UGTs are low affinity enzymes. The 
shapes of the kinetic plots show that saturating concentrations were not reached, and the 
kinetic constants presented here are therefore only approximate values (Table 8). The 
efficiency of the reaction (Vmax/Km) was highest (68 μl/min/mg) for UGT1A8. It must be 
noted that only racemic substrate was available for the assays, which means that the results 
presented for one enantiomer were obtained in the presence of the other. 
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Figure 12. Kinetics of (±)-O-desmethyltramadol (M1) glucuronidation by recombinant human UGTs 
1A8 (A) and 2B7 (B). Eadie-Hofstee plots for each enzyme are given in the insets (I). Panel A: 1R,2R-
	
); Panel B: 1S,2S-	
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(2000 μM) represent the average of two replicates. Conditions as in Table 3. 
This study revealed that several UGTs can catalyse M1 glucuronidation (I), but also that there 
is substantial variability in the stereoselectivity of these catalysts. The homologous UGTs 
1A7–1A10 glucuronidated only the 1R,2R-M1 enantiomer, while the homologues UGT2B7 
and 2B4 preferred the 1S,2S-M1 form. It would be tempting to correlate the observed 
stereoselectivity with the structural similarity of these UGTs. In a recent study of propranolol 
glucuronidation, however, Sten and co-workers [5] showed that sequence similarity of UGTs 
and similar stereoselectivity were not necessarily connected. A corresponding observation 
was made in this study with UGT2B15, which is structurally closely related to UGT2B7 [3]
but displays stereoselectivity more closely resembleing that of the 1A subfamily members.
Clearly, stereoselectivity depends on many complex factors and cannot be predicted solely on 
the basis of primary sequence similarity of the UGTs. 
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On the basis of activity assays and recent expression data [44, 208] it was, for the first time,
established which UGTs contribute to the observed activities in HLMs and HIMs. UGT2B7 
appears to have a key role in (±)-M1 glucuronidation in both tissues: it is particularly well 
expressed in the liver but also in the intestine [44]. It seems probable, therefore, that the 
activity of UGT2B7 is the main contributor to the observed 3-fold higher rate of 1S,2S-M1
over 1R,2R-M1 glucuronidation in the liver (Fig. 12). UGT1A9 is expressed mainly in the 
liver [44] but also in the intestine [121]. UGT1A10 is relatively well expressed in the 
intestine, while the expression of UGTs 1A8 and 1A7 in this tissue is low [44]. This suggests
that UGT2B7 and the “high activity” 1A8 together with the lower activity UGTs 1A7, 1A9,
1A10 and 2B15 (Table 7) are responsible for the production of the two M1 glucuronide 
diastereomers at low but equal rates in the intestine. These results also explain and 
complement (with individual UGTs) the earlier observations that, in humans, 1S,2S-M1 is 
cleared faster than 1R,2R-M1 [165, 199]. A fuller discussion can be found in paper I and 
references therein. 
Taken together, several UGTs were able to catalyse (±)-M1 glucuronidation. The most active 
isoforms were the UGTs 2B7 and 1A8. The UGTs 1A7–1A10 were highly enantiospecific
and recognized only 1R,2R-M1, while UGT2B7 glucuronidated both enantiomers of M1.
5.4 Evaluation of ultra performance liquid chromatography/ electrospray–mass 
spectrometry for determination of O-desmethyltramadol glucuronides (I)
Good chromatographic separation and selective detection were needed to determine the low 
levels of M1Gs produced in the reactions. The UPLC method with gradient elution (organic 
content in the eluent ~5%) provided sufficient retention and complete resolution of the 
analytes (with the 1S,2S-diastereomer eluting first) in less than 3 min (Fig. 11) (I). The good 
resolution and efficiency were largely attributable to the 1.7-μm particles of the column and 
the high pressure of the UPLC system [194]. Furthermore, the ion specific MS detection 
enabled the analysis of incubation samples with minimal sample treatment (see Section 4.4.4).
However, the inorganic buffer salts (phosphates) present in the samples had to be removed 
(see Section 4.4.5) before they reached the ESI source in order to avoid matrix effects [190]
and damage to the ion source [186]. The ESI response also depends on eluent composition. 
As mentioned above, the glucuronides eluted with low organic solvent concentration. A
higher proportion of organic solvent usually increases ionisation efficiency and thereby 
sensitivity of the analysis [6, 186].
The method was partially validated. With ESI/MS detection the method was selective. The 
LODs at signal-to-noise ratio (S/N) of 3 were 0.2 μM, which corresponds to 0.4 pmol of 
glucuronide diastereomer on the column. The LOQ (S/N = 10) for the 1S,2S-diastereomer was 
0.4 μM. Two standard curves were constructed for the 1S,2S-M1G. The linearities were 
adequate, with correlation coefficients (r) 0.981 in the range 0.4–7 μM (n = 10) and 0.988 in 
the range 4–18 μM (n = 5). The LOQ for 1R,2R-M1G was 0.4 μM, and r was 0.971 in the 
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range 0.4–4 μM (n = 8). The within-day repeatability of the method was 15% (RSD %)
except at the LOQ where it was 33%. The between-day repeatability of the method was 12% 
(RSD %) except at the LOQ where it was 30%. Although the repeatability tests showed only 
adequate quantitative performance, the method was regarded as suitable for screening and 
enzyme kinetic purposes. 
5.5 Separation of tramadol metabolites and diastereomeric glucuronides by capillary 
electromigration techniques (II)
The aim of study II was to separate tramadol and its main phase I and II metabolites by CE.
The factors that most affect selectivity of separation were investigated (II). The electrolyte 
and the pH of the separation media are the most important factors to optimise in a CE 
separation. The pKa values of the electrolyte reagent(s) and the functional groups of the 
analytes largely determine what is a suitable pH.
Development of a single run separation for the free (M1, M2, M3, M4, M5) and 
glucuronidated (M1G, M4G and M5G) metabolites of tramadol (Table 2) was particularly 
challenging. Three functional groups of the analytes—carboxylic acid group, phenolic 
hydroxy group and primary, secondary or tertiary amino group—affect the choice of the 
separation pH (Fig. 13). 
As can be deduced from Fig. 13, the glucuronides are zwitterions roughly in the pH range of
3–11, and their net charge and μeff is close to zero in the pH range 5–8. The main focus was 
therefore on pH values above 10. Separations in CAPS (pKa 10.4) and tetraborate (pKa 9.24)
electrolyte solutions were examined, and electrophoretic mobilities of tramadol metabolites
Figure 13. Ionisation of functional groups present in tramadol metabolites M1, M4, M5, M1G, M4G 
and M5G. All analytes have two ionisable groups. The graph is based on the pKa values presented in 
Table 2.
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were calculated in the pH range 9.8–10.8 near the amine pKa values of the analytes (Table 2) 
(II).  
The results indicated that the net charge of the phenolic metabolites (M1, M4 and M5) 
changes from positive to negative as the pH increases from 9.8 to ~10.4. They also showed 
that the zwitterionic glucuronides (M1G, M4G and M5G) have a negative net charge, while 
the O-methylated compounds (tramadol, M2 and M3) are cations. The differences in 
electrophoretic mobility of the analytes were sufficient for separation only at pH 10.65. 
Tetraborate–sodium hydroxide solution was chosen as the BGE. Increasing the tetraborate 
concentration from 50 to 65 mM improved the separation of M5G and M4. A successful CE 
separation of tramadol metabolites was obtained with 65 mM tetraborate solution (pH 10.65)
as the BGE. The electropherogram in Fig. 14 reveals that the migration order is determined by 
the amine pKa value and the net charge of the compound (Table 2). In all three metabolite 
groups the compounds were detected in order of decreasing amine pKa values; i.e.; the 
secondary amine metabolites (M2, M5 and M5G) with highest amine pKa values reached the 
detector first and the tertiary amine metabolites (tramadol, M1 and M1G) with lowest amine 
pKa values were detected last. The negative charge of the phenolic metabolite is smaller than 
Figure 14. CE separation of tramadol and its phase I (M1-M5) and phase II (M1G, M4G, M5G) 
metabolites in tetraborate (65 mM)–sodium hydroxide (162.5 mM) electrolyte solution (pH 10.65)
(II). Conditions as in Table 3. (Voltage 9 kV; Electric field 192 V/cm, current 74 ± 1 μA)
that of the glucuronide and explains why the phenolic metabolite always migrates before the 
respective glucuronide. 
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Tramadol glucuronides were also analysed in low-pH conditions in ammonium acetate–
formic acid BGE (pH 2.75) with minimised EOF (II) (Fig. 15). These experiments showed 
that the zwitterionic glucuronides M1G, M4G and M5G, which now carried a positive net 
Figure 15. Separation of tramadol glucuronides M1G (A), M5G (B) and M4G (C) into diastereomers 
in ammonium acetate (10 mM)–formic acid (100 mM) electrolyte solution (pH 2.75) (II). The first 
migrating diastereomer is the 1S,2S form[165, 199]. Conditions as in Table 3.
charge (Fig. 13), could be separated into diastereomers when the transporting effect of EOF 
was negligible (Fig. 15). The difference in electrophoretic mobility of the diastereomers was 
due to differences in their shapes, charge distribution and pKa values [209]. The individual 
glucuronides (as a mixture) could not be separated under these conditions (Fig. 15, panel D). 
These experiments also revealed that the in vitro enzyme-assisted syntheses of tramadol 
glucuronides with RLMs were stereoselective (Fig. 15).
The effect of SDS in the analysis of tramadol metabolites was examined as well, since the end
purpose was to apply the method for urine samples (II). MEKC separations were performed 
in basic (pH 10.45) 25 mM tetraborate solution with addition of different concentrations of 
SDS (0–90 mM) to the BGE. The addition of SDS affected the migration behaviour of the 
analytes dramatically. Reversal of migration order was observed for both phenolic and 
glucuronide metabolites and, additionally, all three glucuronides M1G, M4G and M5G were 
separated into diastereomers. Separation of the glucuronide diastereomers at SDS 
concentration of 70 mM is presented in Fig. 16. Note that the migration order of the 
diastereomers differs from that found under the acidic CE conditions described above.
Despite the highly selective diastereomeric separation of tramadol glucuronides, the MEKC
method could not be applied for urine samples since interfering matrix compounds in the
migration window of the glucuronides (11-17 min) did not allow unambiguous identification
of the glucuronide diastereomers.
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Figure 16. MEKC separation of tramadol glucuronides in tetraborate (25 mM)–sodium hydroxide (60 
mM)–SDS (70 mM) electrolyte solution (pH 10.45) (II). The first migrating diastereomer is in each 
case the 1R,2R form. Conditions as in Table 3. Sample injection 10 s at 0.5 psi.
The suitability of the CE method to analyse tramadol and its metabolites, was evaluated by 
determining the LODs (S/N of 3 calculated on the peak heights) and repeatability of the 
method (II). The results are presented in Table 9.
Table 9. LOD (μM) for the free and glucuronidated metabolites of tramadol and repeatability of the 
CE method.
CE method
TR M2 M3 M1 M4 M5 M1G M4G M5G
LODa (μM) 0.7 0.7 0.7 1.8 1.5 1.8 6.0 7.0 7.0
Repeatability,
Relative migration timea, RSD (%)
Peak areaa, RSD (%)
0.23
6.7
0.53
6.5
0.49
6.5
1.97
4.3
1.99
3.1
1.53
5.4
1.38
6.3
1.49
6.3
1.32
4.6
TR or, tramadol; an = 6; Conditions as in Table 3. (Voltage 9 kV; Electric field 192 V/cm, current 74 ± 
1 μA)
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The LODs for tramadol glucuronides were relatively high: 6-7 μm. It must be noted, 
however, that the injection time was 3 s (at 0.5 psi) and the injected volume only 3.8 nl. The 
cationic O-methylated metabolites were accelerated by the EOF and migrated as very sharp 
zones, and peaks were easy to distinguish from the baseline noise even at low concentrations
(0.7 μM) (Fig. 14). The relatively large variation in peak areas of tramadol metabolites (RSD 
%, 3.1–6.7%) (Table 9) may be partly due to the low concentrations of analytes in the sample 
solution, short injection time [210] and inaccurate integration of tailing peaks (Fig. 14). 
Precision of relative migration times (RSD % < 2%) indicated adequate repeatability of the 
method.
The applicability of the CE method for identification of tramadol metabolites in urine samples 
was tested with an authentic urine sample collected after administration of tramadol (50 mg)
(II). The test urine (TR-U) sample was purified by SPE using sorbent material that selectively 
retained basic analytes by cation-exchange mechanism. Metabolites were identified by
comparing the purified and 5-fold concentrated TR-U sample with a pre-dose urine sample 
spiked with tramadol metabolites (Fig. 17). The blank sample was virtually free of 
interference and enabled analysis of tramadol metabolites. Comparison revealed five new 
Figure 17. CE electropherograms of a spiked urine sample (A), tramadol urine sample (B) and a
blank urine sample (C) (II). The urine samples were 5-fold concentrated. The peak marked with an 
asterisk refers to an unknown compound or metabolite. Conditions as in Table 3.
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peaks in the electropherogram of the TR-U sample, which, in migration order, were assumed 
to represent tramadol and its metabolites M5, M5G, M1 and M1G. Except for metabolite M2, 
which was not detected in the test sample, the results were largely in agreement with those of 
earlier studies in which unaltered tramadol and metabolites M1, M2, M5, M1G and M5G 
were detected in urine [91, 93]. The metabolites M4 and M4G, regarded as minor metabolites 
[91, 93], were not found in the test sample. The method was concluded to be suitable for 
identifying the main metabolites of tramadol in authentic urine samples. Generally, 
comparison with standards as the sole identification method is not recommended and should 
only be resorted to when more sophisticated methods are not available.
5.6  Separation of the glucuronides of entacapone and its (Z)-isomer by micellar 
electrokinetic chromatography (III)
The objective of study III was to develop a direct bioanalytical method— that relies on 
capillary electromigration techniques with UV detection—for the separation of the 3-O-
glucuronides of entacapone and its (Z)-isomer in urine (Table 2). As in study II, pH and 
composition of the BGE were investigated to optimise the separation.
Separation of EG and EZG and the structurally related IS, NG (Fig. 1 in III), was investigated
in phosphate–borate–SDS electrolyte solutions of three different concentrations (III).
Separation was evaluated in the pH range 5–8 where all three glucuronides exist mainly as 
doubly charged anions owing to the two ionisable groups in their structures (Table 2). The 
glucuronides were well separated in the pH range 6–8 in all three electrolyte solutions tested
and pH 7 was regarded as the optimal pH for the separation. The electrolyte solution of 
highest ionic concentration (25 mM of phosphate, 50 mM of borate and 20 mM of SDS) gave 
the best resolution (RS 1.26) for the glucuronides and was selected for the method. Under
normal polarity conditions all three glucuronides migrated against the EOF. EG had lower 
mobility than EZG (tm ~15.5 min) and was transported to the detector first (tm ~15 min). NG,
being of smaller size (smaller MW), had highest electrophoretic mobility towards the anode 
and was detected last (tm ~16 min).
Preliminary studies had revealed that EG and EZG could be separated by CE (III). The effect 
of SDS (20–60 mM) in the electrolyte solution was examined, but no essential improvement 
in the separation of the analytes was achieved. The result is consistent with the findings of 
Zhang and Thormann [211] who reported that negatively charged SDS micelles have little 
effect on anionic opioid glucuronides due to electrostatic repulsion. SDS at concentration of 
20 mM was nevertheless added to the BGE to increase selectivity in the complex urine matrix 
(III). A further benefit was the ability of SDS to solubilise urinary proteins and prevent their 
adsorption on the capillary wall [212]. Which factors caused separation of diastereomers EG 
and EZG in this case, remains unclear.
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Before the method was applied to the analysis of urine samples, sensitivity of the instrument 
and the overall performance of the method were briefly tested for aqueous samples (III). The 
LODs for EG and EZG were 0.25 μg/ml (~0.5 μM). The good within-day precision of the 
relative migration times (RSD% 0.4%, n=19) and peak areas (RSD% <1.5%, n=6) together 
with constant current (~40 μA) and temperature (25 ± 0.1°C) indicated stable separation 
conditions of the MEKC method (III). 
5.7 Validation of micellar electrokinetic chromatography method for quantitative 
analysis of glucuronides of entacapone in human urine (IV)
The suitability and reliability of the MEKC method for quantitative analysis of the 
glucuronides of entacapone in urine were evaluated in validation experiments according to the 
guidelines of Shah et al. (1991) [213] (IV). To improve selectivity and sensitivity, an SPE 
procedure was included in the method (Table 4). Important validation parameters, such as 
identification of the analytes, selectivity, LOQ, linearity, repeatability (within-day and 
between-day) and extraction recovery, were investigated both before and within the study. 
Essential CE-specific aspects (e.g., EOF stability, repeatability of injection) as well as analyte 
stability during the analysis were evaluated as well. Validation results are summarised in 
Table 10 and discussed below. More detailed results can be found in the original publication 
IV.
5.7.1 Identification of glucuronides
Enzymatic hydrolysis was carried out to confirm the identity of the analytes (IV). A blank 
urine sample spiked with reference glucuronides EG and EZG, an authentic urine sample 
collected for 12 h after entacapone (200 mg) administration, and a pre-dose urine sample (data 
not shown) were hydrolysed in parallel (Fig. 18). When the spiked urine sample (panel A1) 
was incubated for 20 min at 37 '?  -glucuronidase (from E. coli) the two synthetic 
reference glucuronides were almost completely hydrolysed and a new compound was detected 
in the electropherogram. The new peak represented entacapone and its (Z)-isomer, which co-
migrated with a tm of ~12 min. Similar changes were observed in panel B1 in the 
electropherogram of the authentic urine sample, which indicated that the compounds with 
similar migration times are identical. Hydrolysis was not observed in the control samples 
(panels A3 and B3) incubated in the same way but without the enzyme. The hydrolysis was
clearly -glucuronidase-dependent since it could be prevented by a specific enzyme inhibitor, 
D-saccharic acid 1,4-lactone (panels A2, B2). These results verified the conjugates in the 
authentic urine sample as glucuronides. Enzymatic hydrolysis in the absence and presence of 
specific enzyme inhibitor thus provides a practical and reliable way to identify glucuronide 
metabolites.
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Figure 18. Identification of the analytes in hydrolysis experiments (IV). Blank urine spiked with the 
glucuronides of entacapone (A) and an authentic urine sample (B) were incubated at 37 °C for 20 min 
!
-glucuronidase in the absence (panels A1 and B1) and presence (A2 and B2) of D-saccharic 
acid-1,4-lactone, a specific inhibitor of -glucuronidase. Control samples were incubated without the 
enzyme (panels A3 and B3) or frozen immediately (panels A4 and B4). Peaks: EG (1), EZG (2) and 
entacapone in co-migration with its (Z)-isomer (3). Conditions as in Table 3.
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5.7.2  Selectivity and limit of quantification
Selectivity and LOQ were determined in a single set of experiments (IV). Selectivity was 
evaluated on the basis of six pre-dose urine samples. The electropherograms showed that the 
migration window of the analytes and the IS (the region after 15 min) was relatively free from 
interferences and would allow the determination of EG and EZG (Fig. 3 in IV and Fig. 19 
below). The LOQ for the analytes was determined to be 2 μg/ml (4.16 μM). At this 
concentration the S/N for both glucuronides was >10 (Table 10). 
5.7.3  Linear range, within-day precision and recovery
The linear range, within-day precision (repeatability of the method) and recovery were 
determined in a single set of experiments (IV). Corrected peak areas instead of heights were 
Table 10. Validation results of the MEKC/UV method used for quantitative bioanalysis of EG and 
EZG in human urine.
MEKC/UV
LOD
LOQ
Linearity
0.25 μg/ml  (~0.5 μM)  (S/N = 3)
2 μg/ml (4.16 μM) for EG and EZG
(S/N = 14 for EG and 12 for EZG)
(r2)  0.998 for EG and EZG
2 – 150 μg/ml   (4.16 – 312 μM)
Repeatability (RSD %)
Repeatability of the methoda
within-day precision
Repeatability of injectiona
injection precision
Recovery of extractiona
(repeatability of extraction)
Reproducibility of the methodb
between-day precision
relative migration times
within-day precisionc
(repeatability)
between-day precisiond
(reproducibility)
for EG
for EZG
for EG
for EZG
for EG 
for EZG
for NG (IS)
for EG and EZG
for EG      0.72
for EG      1.38  
< 3.25;   at LOQ 3.66
< 3.04;   at LOQ 4.87
< 0.96;   at LOQ 2.44
< 0.73;   at LOQ 2.82
> 94.3
> 96.9
> 90.7
< 7.5 at lower (7.5 μg/ml) concentration
< 5.5 at higher (75 μg/ml) concentration
for EZG     0.74
for EZG     1.46
a three concentrations, n=6/ concentration, bn=9, cn=22, dn=17 (pre-dose urine samples not included)
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used for calibration since this mode commonly yields good linear correlations [157, 214]. The 
linearity data for EG and EZG are shown in Table 10. In the validation experiments a slight 
deviation from linearity was observed at the highest calibration point (150 μg/ml), which 
indicated that the concentration range selected (2–150 μg/ml) was somewhat too wide. The 
highest calibration samples also gave asymmetric peaks, providing further evidence of 
capillary overloading (Fig. 4 in IV) and underlining the importance of determining the 
“upper” LOQ as well.
Repeatability of the method and injection as well as recovery of the extraction were tested at 
three concentrations representing the entire range of calibration (IV). The results are 
summarised in Table 10. The results were obtained with use of IS (at concentration 15 μg/ml)
and show good repeatability of the method. The tests for injection repeatability revealed that,
except at LOQ, the precision values (RSD% ~1%) were near the target value (RSD% <1%)
set for repeatable sample loading [157] (Table 10). Also, precision of the relative migration
times of the analytes (RSD % ~0.74%, n=22) indicated that the method conditions give a 
stable and repeatable separation.
Although use of IS generally improves quantitative performance of CE methods,
improvements in precision values were not (in all cases) observed in this study (IV). In the 
method repeatability tests the RSD values for IS were slightly larger than those of the analytes
(data not shown here) and this was reflected in the results (corrected Aanalytes/corrected AIS) as 
somewhat poorer precision except at the highest analyte concentration. As shown in Table 10 
the extraction recovery of the IS was also lower than that of the analytes and may explain why 
RSD values for repeatability were higher for NG than for the analytes. In this study,
incorporation of an IS was considered necessary, however, to compensate not only for 
variability of injection but for errors arising during sample preparation and treatment.
5.7.4 Between-day precision and accuracy
Validity of the method was also evaluated during the five analysis days. The between-day 
precision (reproducibility of the method) and accuracy were determined on the basis of 
quality control (QC) samples (IV). For both glucuronides the observed inaccuracy was about 
+2.5% at lower (7.5 μg/ml) and +5.6% at higher (75 μg/ml) concentration levels (n=9). The 
between-day precision for both glucuronides gave RSDs <7.5% (Table 10). The between-day 
precision value of the relative migration times was clearly higher (RSD% ~1.46%, n=17) than 
the within-day value.
Overall the glucuronides behaved very much the same in all validation experiments. Although 
use of IS was not questioned in this study, a higher concentration of IS might have minimised 
integration errors and improved precision. In any event, the validation experiments indicated
that the MEKC method was repeatable and suitable for the intended purpose (IV).
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5.7.5 Stability of entacapone glucuronides
The stability of entacapone glucuronides was examined by analysing a spiked urine sample 
and an aqueous reference sample in duplicate (IV). The test sample was allowed to stand in 
the autosampler at room temperature for 4.5–5 h, whereafter it was re-analysed together with 
a freshly prepared reference sample. No essential changes were observed in the two 
electropherograms. The corrected peak area ratio, EG/EZG, for the test sample was 1.34 and 
1.33 before and after storage, and consistent with that of the two reference samples (1.34 and 
1.32). Additional information on the stability of entacapone glucuronides was obtained from 
the hydrolysis experiments (see Section 5.7.1). No significant changes in the corrected peak 
areas of EG and EZG were observed when the spiked control sample, incubated in phosphate 
buffer (pH 6.85) at 37 °C for 3 h, was compared with the immediately frozen control sample. 
It can be concluded that EG and EZG are relatively stable; neither isomerisation nor non-
specific hydrolysis occurred under the experimental conditions.
5.8 Analysis of patient urine samples (IV)
The applicability of the MEKC method was tested with urine samples collected from 34
patients after an oral (200 mg) or i.v. (25 mg) dose of entacapone (IV). Since the 
concentration range was wide, separate calibration curves were used for the low and high
concentrations. The calibration curves were constructed by using five data points in the range 
2–75 μg/ml and four in the range 50–150 μg/ml. Except for one calibration, correlation 
coefficients (r) were better than 0.999 in the range 2–75 μg/ml. The r values were not so good
(> 0.9915) in the range 50–150 μg/ml. The differences between nominal concentrations and 
the mean determined concentrations of the calibration samples were calculated. The largest 
difference for both analytes was found at the LOQ, where the deviation from the nominal 
value (“systematic error”) was about ± 16% (Table 5 in IV). At the other calibration points 
the difference was considerably smaller: <4% except at the calibration point 100 μg/ml where 
it was about 7%. 
The average concentration of EG in the urine samples was >30 μg/ml after oral administration 
and about 10 μg/ml after i.v. administration (IV). The concentration of EZG could usually be 
determined only after oral entacapone administration, when it was 5–25 μg/ml. After i.v. 
dosing the concentration of EZG was generally under the LOQ. Typical electropherograms of 
two patient samples are shown in Fig. 19.
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Figure 19. Typical electropherograms of two patient samples before (lower panel) and after (upper 
panel) administration of entacapone. Urine was collected 0-12 h after an oral (200 mg) dose (A) and 
after an i.v. (25 mg) dose (B) of entacapone. The relative concentration of EZG is higher after oral 
administration than after i.v. administration. The determined concentrations were in A 50.71 μg/ml (1) 
and 20.63 μg/ml (2) and in B 10.93 μg/ml (1) and <2μg/ml (2). Peaks as in Fig. 18. The concentration 
of IS is 15 μg/ml. Conditions as in Table 3. 
The experiments also showed that the mode of administration, oral or i.v., affects entacapone 
metabolism (IV). The relative proportion of EZG in urine was evaluated by calculating the 
ratio corrected peak AEZG/corrected peak AEG+EZG for ten samples of each type. The value of
the ratio was 2.5-fold higher after oral than after i.v. administration (see also Fig. 19). The 
results strongly suggest that entacapone, when administered orally, is metabolised in notable 
amount to its (Z)-isomer during first-pass metabolism in the intestine and liver.
Steady EOF indicates proper performance of the CE capillary. The within-day precision of 
relative migration times was good for both analytes in validation trials, but the variability was 
greater when patient urine samples were analysed (Table 10). This variability was probably 
related to the endogenous components present in urine matrices, some of which adhere to the 
capillary wall and alter its performance (IV). Clearly, validation experiments do not 
necessarily reveal all critical steps of the analytical procedure. CE methods for bioanalytical 
applications must be extremely robust, and numerous factors must be taken into account when 
the methods are optimised and validated for quantitative bioanalysis. 
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6 SUMMARY AND CONCLUSIONS
Diastereomeric glucuronides, the 3-O-glucuronides of O-desmethyltramadol (M1Gs) and the 
3-O-glucuronides of entacapone and its (Z)-isomer (EG and EZG), were the main targets of 
this research. Analytical methods based on LC/UV, LC/MS, CE/UV and MEKC/UV were 
developed and optimised for the separation and direct quantitative determination of the 
compounds from complex matrices. M1Gs were enzymatically synthesised as reference 
compounds, and NMR spectroscopy was used to elucidate the structures of the isolated 
products.
Glucuronide conjugates of (±)-O-desmethyltramadol (M1) were enzymatically produced with 
use of RLMs as the UGT enzyme source. The enzymatic reaction was stereoselective and the
formation of 1S,2S-M1G was preferred over the 1R,2R-diastereomer. The biosynthesis was 
found to be a suitable way to obtain reference glucuronides for method development and 
calibration from small amounts of starting material (substrate). A clear benefit of the 
enzymatic reaction was the selective production of -anomers only. The product glucuronides 
formed from racemic M1 were purified by SPE and fractionated by HPLC/UV into separate 
fractions for identification or they were collected as a combined fraction for reference 
material. The yield in the latter case was 51%.
The collected fractions were confirmed as M1 monoglucuronides by UPLC/ESI-MS. The 
glucuronides were assumed to be diastereomers on the basis of their closely similar MS/MS 
spectra. NMR spectroscopy, particularly NOESY, provided the valuable information on the 
glucuronidation site, which was shown to be the phenolic hydroxy group of M1, as earlier 
proposed. It followed from this that the glucuronides were indeed diastereomers. The final 
step in the structural characterisation, the identification of the 1R,2R- and 1S,2S-glucuronide 
diastereomers, was carried out on the basis of earlier publications.
Screening assays with human recombinant UGTs revealed, for the first time, that several 
UGTs are capable of glucuronidating M1-enantiomers. They also revealed great variability in 
stereoselectivity among the UGTs. Substrate specific redundancy and complete 
enantiospecificity towards 1R,2R-M1 were confirmed for the UGTs 1A7–1A10. Isoform 
UGT2B7 accepted both enantiomers of M1 as substrates but glucuronidated the 1S,2S-M1 at 
higher rates. The activity of HLMs towards (±)-M1 largely resembled the activity of 
UGT2B7, and it was concluded that UGT2B7 is the main isoform responsible for the activity 
of HLMs. The activity of HIMs towards (±)-M1 was low and the two enantiomers were
equally glucuronidated. Also in this tissue, UGT2B7 appears to be an important isoform in
(±)-M1 glucuronidation, although the contributions of the “high activity” UGT1A8 and lower 
activity UGTs 1A7, 1A9, 1A10 and 2B15 must not be forgotten.
Positive ion mode UPLC/ESI-MS was a fast and selective tool for the analysis of M1Gs in
activity assay samples. Only minimal sample preparation was required. UPLC provided the
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complete separation of the M1G diastereomers, essential for their quantification. LODs were 
0.2 μM and LOQs ~0.4 μM. Although the repeatability of the method was only adequate, it
was regarded as acceptable for screening and enzyme kinetic purposes.
CE/UV was applied for the analysis of free and glucuronidated metabolites of tramadol. Nine 
analytes with different polarities and six metabolites with two ionisable groups made the 
selection of separation pH challenging. Baseline separation of the free and glucuronidated 
metabolites was achieved with 65 mM tetraborate solution (pH 10.65) as the BGE. The 
applicability of the method was tested with an authentic urine sample after tramadol 
administration. With use of synthesised standards, tramadol and its main metabolites (M1, 
M1G, M5 and M5G) could be identified in the 5-fold concentrated urine sample. 
Additionally, diastereomeric separation of glucuronide metabolites was obtained by CE/UV 
in acidic electrolyte solution (pH <3) or by MEKC/UV in basic electrolyte solution (pH 
10.45). The latter method provided a highly selective diastereomeric separation of tramadol 
glucuronides, but owing to interfering peaks it was unsuitable for urine samples.
MEKC is an established capillary electromigration technique for bioanalytical applications. A 
MEKC/UV method was therefore developed for separation of EG and EZG in urine matrix,
and NG was chosen as IS. The optimised method, employing a phosphate (25 mM)–borate 
(50 mM)–SDS (20 mM) solution (pH 7) as the BGE, provided baseline resolution of the three 
glucuronides. With an SPE purification step added, the method was then systematically 
validated for the direct determination of EG and EZG in urine samples. The LOQ for both 
glucuronides was 2 μg/ml, or 4.16 μM. The range selected for validation (2–150 μg/ml) was 
somewhat too wide and resulted in slight deviation from linearity at the highest calibration 
point. The determination of the “upper” LOQ is important as well, therefore. In this study, use 
of IS did not improve quantitative performance of the method, probably because its 
concentration in the samples was too low.
The validation experiments confirmed that the MEKC method was repeatable and suitable for 
the intended purpose. In the five-day analytical trial in which urine samples of 34 entacapone-
treated patients were analysed, difference were observed in the relative migration times of the 
analytes, which indicated changes in the EOF and capillary performance. Clearly, even very 
careful validation beforehand cannot reveal all sample-related factors (e.g., matrix effects) 
that may affect capillary performance. A higher concentration of SDS or higher pH of the 
BGE might have reduced the matrix effects.
The MEKC method allowed the determination of EG after both oral and i.v. administration of 
entacapone. The concentration of EZG could usually be measured only after oral entacapone 
dosing. The analyses also revealed that the mode of administration affects the metabolic 
profile of entacapone; the relative amount of EZG in urine was higher after oral 
administration and strongly suggested that first-pass metabolism of entacapone to its (Z)-
isomer takes place in the intestine and liver after oral entacapone administration.
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Short-term stability of M1 glucuronides (24 h in water at 22 °C) and entacapone glucuronides 
(~5 h in urine at 23 °C or 3 h in phosphate buffer at 37 °C) was studied as well. Both these 
ether-structured glucuronides proved to be stable under the test conditions.
Enzymatic glucuronidation offers a simple way to produce glucuronide conjugates for use as 
reference compounds. With use of recombinant UGTs or tissue microsomes, the 
glucuronidation reaction provides a valuable tool for in vitro metabolic and pharmacokinetic 
studies. Stereoisomers are interesting substrates for the studies, since, as was shown here, 
some of the UGTs display considerable stereoselectivity. 
Capillary electromigration techniques and LC are popular tools in glucuronide analysis. In 
bioanalytical applications CE and MEKC, in spite of their good resolving power, suffer from 
limited sensitivity and long-term stability. UPLC/ESI-MS is a fast, efficient and selective 
technique. As shown in the work presented here, it is capable of resolving glucuronide 
diastereomers as well. The UPLC/ESI-MS technique offers a powerful approach for the 
separation, detection and identification of low concentration drug metabolites.
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